Lyonbiopôle€¦ · 11ÈME N N COLLABORATIVE DE LYON BIO PÔLE 10 OCTOBRE 017 . 3. Nous sommes très heureux de vous retrouver pour la 11. ème. édition de la Journée Collaborative

Auvergne Rhône Alpes- -

JOUR N É E C O L L A B O R AT I VE

L E C A H I E R D E L A J O U R N É E C O L L A B O R A T I V E

1 1 E É D I T I O N - M A R D I 1 0 O C T O B R E 2 0 1 7 / H Ö T E L D E R É G I O N - LY O N C O N F L U E N C E

C O N F É R E N C E D ’ O U V E R T U R E

T A B L E S R O N D E S

B L U E S K YM E E T I N G

N E T W O R K I N G

Avec le soutien de

Gold Sponsors

Avec la participation de

3 11ÈME ÉDITION JOURNÉE COLLABORATIVE DE LYONBIOPÔLE 10 OCTOBRE 2017

Nous sommes très heureux de vous retrouver pour la 11ème édition de la Journée Collaborative de Lyonbiopôle. Cet évènement a pour but de créer du lien entre les quatre communautés de la région Auvergne-Rhône-Alpes en santé (PME, grands groupes, centres de recherche publics et cliniciens) avec lesquelles Lyonbiopôle interagit.

Cette initiative unique en son genre permet sur une même journée de faire travailler ses participants en tables rondes sur de grands enjeux médicaux et scientifiques, de mettre en lumière les expertises de l’écosystème, de présenter des projets collaboratifs en cours ou à venir et enfin, à travers le Bluesky Meeting, de donner la parole à des PME et des laboratoires en recherche de partenaires.

Les éditions précédentes ont réuni plus de 2 600 participants et fédéré une communauté d’experts autour de 157 tables rondes. Cadre privilégié pour échanger sur les défis majeurs en santé, pour réfléchir aux axes stratégiques à adopter et permettre la conception de solutions innovantes, la Journée Collaborative est aujourd’hui l’outil phare d’animation scientifique et technologique du pôle.

Avec ce rendez-vous annuel des acteurs publics et privés de la santé, Lyonbiopôle joue son rôle de catalyseur de l’écosystème régional, favorise l’émergence de produits biotech et medtech innovants et renforce le développement économique du territoire.

Le succès de cette journée repose également sur l’implication de nombreux partenaires rassemblés dans cette démarche : l’association ACCINOV, l’Institut de Recherche Technologique BIOASTER, le Centre Européen de Dermocosmétologie (CED), le Centre Européen de Nutrition pour la Santé (CENS), le cancéropôle CLARA, le cluster I-CARE, l’association MABDESIGN, l’agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), le pôle catalan BIOCAT, la mutuelle HARMONIE MUTUELLE et le Syndicat National de l’Industrie des TEchnologies Médicales (SNITEM).

Les sujets abordés cette année reflètent les savoir-faire de l’écosystème mais aussi le renouvellement des sujets qu’un pôle santé doit accompagner aujourd’hui.

Nous vous souhaitons des échanges fructueux et l’émergence de partenariats pour répondre à l’ensemble de ces enjeux.

L’équipe de Lyonbiopôle

EDITORIAL

11ÈME ÉDITION JOURNÉE COLLABORATIVE DE LYONBIOPÔLE 10 OCTOBRE 2017 4

PROGRAMME de la journée


8:00 - 9:00 ACCUEIL DES PARTICIPANTS

9:00 - 9:10 MOT DE BIENVENUE Yannick Neuder, Région Auvergne-Rhône-Alpes 9:10 - 9:25 INTRODUCTION Christophe Cizeron, Lyonbiopôle Florence Agostino-Etchetto, Lyonbiopôle

9:25 - 10:10 CONFÉRENCE D’OUVERTURE Patrick Lévy, UGA

10:15 - 12:45 TABLES RONDES DE BRAINSTORMING

12:45 - 14:00 COCKTAIL DÉJEUNATOIRE 14:00 - 15:00 RESTITUTION DES TABLES RONDES

15:00 - 17:15 BLUESKY MEETING 17:15 - 19:00 TIRAGE AU SORT DE L'APPGAME ET NETWORKING


Conférence d’ouverture9:25 -10:10CONFÉRENCED’OUVERTURESalle du conseil


PATRICK LEVY UGA

Innovations en santé et médecine du futur

Patrick Lévy est Docteur en Médecine, Pneumologue (1983) et Professeur des Universités depuis 1989 (physiologie). Président de l’Université Joseph Fourier à Grenoble depuis 2012, Patrick Lévy a été élu à la Présidence de la Communauté Université Grenoble-Alpes en décembre 2015. Il est porteur du projet labellisé Initiative d’Excellence «IDEX Université Grenoble Alpes : université de l’innovation» depuis 2016. Il assure également depuis 2012 la présidence de l’UNF3S (Université Numérique Francophone des Sciences, de la Santé et du Sport).

Patrick Lévy a dirigé depuis 1988 l’exploration fonctionnelle respiratoire et le laboratoire du sommeil du CHU de Grenoble. Parmi diverses responsabilités hospitalières, il a été à la tête du pôle rééducation et physiologie de la délégation régionale pour la recherche clinique et l’innovation et du pôle recherche du CHU de Grenoble. Depuis plus de vingt ans, Patrick Lévy a développé la recherche clinique dans le domaine des apnées du sommeil, dont Grenoble est aujourd’hui l’un des centres de référence en Europe. En 2002, il a mis en place le laboratoire HP2 (Hypoxie PhysioPathologie). Il a été Président de la Société française de recherche de médecine du sommeil (1999-2001), Fondateur et Président de l’Institut national du sommeil et de la vigilance (2000-2007). Il a aussi occupé le poste de Vice-président de l’European Sleep Research Society (2009 -2012). En 2013, Patrick Lévy a été nommé Chevalier de la Légion d’honneur, avant de recevoir en 2015, le prestigieux prix Jean-Claude Yernault lecture à Barcelone, qui récompense ses travaux de plus de 25 ans en recherche et pratique clinique sur l’apnée du sommeil.


Conférence d’ouverture10:15 - 12:45TABLES RONDESDE BRAINSTORMINGSalles parallèles


Bioproduction

Biologie cutanée

E-santé/parcours de soin

Immunologie

Maladies osseuses

TR 1 - L’usage unique en bioproduction : quelles innovations dans les systèmes clos, des banques aux produits finis ?

TR 2 - Microbiote cutané : quelles applications en santé ?

TR 3 - Monitoring de patient à domicile : quels paramètres suivre, pour quelles applications et quelle population ?

COORGANISATEURS THÈMES

20 TABLES RONDES de brainstorming

E-santé/parcours de soin

TR 4 - Systèmes numériques d’aide à la décision médicale : quelles technologies pour quels usages ?

ImmunologieTR 5 - Immunogénicité des biomolécules thérapeutiques : quels facteurs et comment la prédire et l’analyser ?

Maladies infectieuses TR 6 - Diagnostic Point of Care : quelles innovations technologiques ?

Maladies infectieusesTR 7 - Modulation du microbiote et lutte contre les résistances bactériennes chez l’homme et l’animal

Maladies infectieusesTR 8 - Vaccination et état nutritionnel : comment améliorer la réponse vaccinale ?

Médecine régénérative TR 9 - Greffe de cellules souches : barrières technologiques et enjeux thérapeutiques


Technologies

Oncologie TR 11 - New insights in immunology and cancer therapy

OncologieTR 12 - Mécanobiologie et contrôle de l’environnement cellulaire : applications pour la caractérisation des tumeurs

*TR 13 - Comment mesurer la toxicité des nanoparticules ?

Technologies

Technologies

Technologies

Technologies

Technologies

Technologies

TR 14 - Use of nanoparticules in targeted therapies: which added value?

TR 15 - Quel avenir pour le deep learning en imagerie médicale ?

**TR 16 - Biomatériaux innovants, vers une évolution des dispositifs médicaux

TR 17 - Dispositifs médicaux invasifs (stents, prothèses, cathéters) : vers l’intelligence et la fonctionnalisation

TR 18 - Impression 3D : impact sur le prototypage, la petite série et la personnalisation des dispositifs médicaux

TR 19 - Nouvelles technologies de criblage pour identifier des hits/leads dans les banques de molécules

VétérinaireTR 20 - Quelles spécificités des formulations et systèmes d’administration en santé animale ?

Nutrition santéTR 10 - Quelle place pour les pré/probiotiques dans la lutte contre les maladies inflammatoires chroniques et l’obésité ?

*La TR13 est fusionnée avec la TR 14**La TR16 est fusionnée avec la TR 17


Biographies - Animateurs des tables rondes

Après avoir travaillé plusieurs années en développement de procédés biotechnologiques et en contrôle qualité chez Merial et Vivalis, Sandrine Aspa a rejoint en 2009 NNE, ingénierie spécialisée pour l’industrie pharmaceutique, pour intégrer l’équipe Process. Elle est en charge des lots équipements process biotech et laboratoires, des études de conception jusqu’à la réalisation des projets.

Sandrine ASPANNE TR 1 : L’usage unique en bioproduction : quelles innovations dans les systèmes clos, des banques aux produits finis ?

Mathieu Bey est responsable R&D pour le développement des activités cosmétiques et pharmaceutiques en microbiologie de Greentech. Plusieurs projets de recherche en collaboration ont permis de mettre en place un savoir-faire dans le domaine de la production de souches probiotiques de nouvelle génération. Cette expertise en matière de microbiologie couplée au savoir-faire de Greentech dans le domaine cosmétique ont donné naissance à une nouvelle forme d’ingrédient actif utilisant le potentiel des micro-organismes.

Mathieu BEYGREENTECH TR 2 : Microbiote cutané : quelles applications en santé ?

Aujourd’hui Directeur de la filière “Données et Innovation” chez Harmonie Mutuelle, Marc Richard était auparavant Directeur de l’Innovation Numérique et, précédemment encore, Directeur des Systèmes d’Information (DSI) pendant plus de 13 ans d’une des composantes du groupe Harmonie Mutuelle, né de la fusion de 6 mutuelles, avec la mise en place d’un système d’information unique et très digitalisé.

Marc RICHARDHARMONIE MUTUELLE TR 3 : Monitoring de patient à domicile : quels paramètres suivre, pour quelles applications et quelle population ?

Sylvain PEYRACHEACCINOV TR 1 : L’usage unique en bioproduction : quelles innovations dans les systèmes clos, des banques aux produits finis ?

Après avoir travaillé en physico-chimie et formulation de protéines thérapeutiques chez Adocia, Sylvain Peyrache a rejoint Sanofi Pasteur pour animer un réseau d’expertise et de veille technologique. En 2012, il a eu l’opportunité de rejoindre Accinov pour coordonner les projets pharmaceutiques des clients de la société. Il est désormais en charge du transfert et de l’industrialisation des produits fabriqués dans les ateliers d’Accinov.


Chef de service du Département d’Information Médicale et de Valorisation de l’Activité du CHU de Clermont-Ferrand, responsable de l’Information Médicale du GHT « Territoires d’Auvergne ». Docteur en médecine, titulaire d’un DEA d’informatique médicale et d’une licence de biologie moléculaire, impliqué depuis plus de 20 ans dans les différentes thématiques de l’informatique appliquée aux domaines de la santé, en particulier sur le pilotage hospitalier et les différents outils d’analyse de données.

Jean-Christophe JOURDYCHU CLERMONT-FERRAND TR 4 : Systèmes numériques d’aide à la décision médicale : quelles technologies pour quels usages ?

Bernard Maillere est directeur de recherche et chef du laboratoire d’immunochimie de la réponse immunitaire cellulaire au CEA. Il a obtenu un doctorat en immunologie en 1992 et l’habilitation à diriger les recherches en 2000. Ses travaux portent sur la prédiction de l’immunogénicité et la réponse des lymphocytes T chez l’homme dans la perspective de développement de nouveaux vaccins et de protéines thérapeutiques. Il est membre du Labex LERMIT et directeur du pôle immunologie/biothérapie de l’école doctorale ED569 innovation thérapeutique.

Bernard MAILLERECEATR 5 : Immunogénicité des biomolécules thérapeutiques : quels facteurs et comment prédire et l’analyser ?

Christophe Védrine a un doctorat en biotechnologie de l’école des Mines de Saint-Etienne. En 2004, il a intégré le CNAM en tant que maître de conférences. Sa recherche portait sur des biocapteurs à ADN, à cellules entières et à polymère conducteur à empreintes moléculaires. De 2008 à 2014, en tant que chef de projet (Bio-Rad), il a développé des technologies multiplexées de diagnostic in vitro. Il est maintenant responsable de recherche à BIOASTER au sein de l’unité microfluidique-microsystème.

Christophe VEDRINEBIOASTER TR 6 : Diagnostic Point of Care : quelles innovations technologiques ?

Ancien élève de l’ENS, agrégé de Biologie, DVM, PhD, HDR, DU Antibiotiques Antibiothérapie (Paris VIII). Directeur de recherches, Chef de l’unité Antibiorésistance et virulence bactériennes (Anses Lyon), Directeur Scientifique Antibiorésistance de l’Anses. Très impliqué dans la surveillance de l’antibiorésistance animale et les démarches inter-ministérielles contre l’antibiorésistance. Activités de recherche centrées sur les mécanismes moléculaires de l’antibiorésistance et le lien Homme-animal.

Jean-Yves MADECANSES TR 7 : Modulation du microbiote et lutte contre les résistances bactériennes chez l’homme et l’animal


Médecin responsable de l’Unité Neurovasculaire (Neurologie) du CHU de Grenoble et attaché au Grenoble Institut des Neurosciences. Ses travaux de recherche cliniques et expérimentaux portent sur l’étude de la récupération après un Accident Vasculaire Cérébral (AVC) avec l’utilisation de la thérapie cellulaire et de biomatériaux injectables. Il est coordinateur d’un projet européen H2020 translationnel sur ce thème (RESSTORE, www.resstore.eu).

Olivier DETANTECHU GRENOBLE TR 9 : Greffe de cellules souches : barrières technologiques et enjeux thérapeutiques

Hubert Vidal est Directeur de Recherche à l’INSERM et Directeur du Laboratoire CarMeN « Cardiovasculaire, Métabolisme, Diabétologie et Nutrition » à Lyon. Ses travaux portent sur les mécanismes d’adaptation à l’environnement chez l’homme (nutrition, microbiote intestinal, pollution, activité physique) dans le contexte des maladies métaboliques (obésité-diabètes). Il est l'auteur de plus de 225 publications (Facteur H = 57) et est un des co-fondateurs du Centre Européen de Nutrition pour la Santé (CENS).

Hubert VIDALINSERM - CARMEN TR 10 : Quelle place pour les pré/probiotiques dans la lutte contre les maladies infammatoires chroniques et l’obésité ?

Violeta Serra obtained her PhD in 2001 in the field of cellular aging from Newcastle University (UK). In 2006, she joined José Baselga’s group at the Vall d’Hebron Institute of Oncology (VHIO) to explore the mode of action and mechanisms of resistance to PI3K and CDK4/6 inhibitors. She now leads the Experimental Therapeutics Group, and continues to expand her research into targeted therapies in triple negative breast cancers, including PARP inhibitors.

Violeta SERRAVALL D’HEBRON INSTITUTE OF ONCOLOGY (VHIO) TR 11 : New insights in immunology and cancer therapy

Daniel Floret est pédiatre, professeur émérite à l’Université Claude Bernard de Lyon. Chef de service honoraire (Urgences et Réanimation pédiatrique) au CHU de Lyon il a également dirigé une unité d’infectiologie pédiatrique et vaccinologie. Membre du Conseil Supérieur d’Hygiène Publique de France puis président du Comité Technique des Vaccinations au Haut Conseil de la Santé Publique de 2016 à 2017. Il est actuellement Vice Président de la Commission Technique des Vaccinations de la HAS.

Daniel FLORETCHU LYON TR 8 : Vaccination et état nutritionnel : comment améliorer la réponse vaccinale ?


Prof. Anna Roig leads the Nanoparticles and Nanocomposites Group (www.icmab.es/nn) at the Materials Institute of Barcelona (ICMAB-CSIC). Her scientific drive is towards understanding nanoparticles in biological milieus and to validate nanomaterials in applications related to Nanomedicine. She graduated in Physics and PhD from the Autonomous Univ of Barcelona, completed her education at the KTH (Sweden) and Northeastern Univ (USA) and served two years in RTD at the European Commission. Researcherid: E-7616-2011.

Anna ROIGICMAB-CSIC TR 14 : Use of nanoparticules in targeted therapies : which added values?

Carole Lartizien est chargée de recherche CNRS au sein du laboratoire CREATIS à Lyon. Elle s’intéresse à l’analyse statistique des données d’imagerie médicales permettant d’extraire l’information pertinente pour orienter le diagnostic, mieux comprendre les mécanismes de la pathologie et prédire son évolution ou adapter le traitement. Ses activités de recherche comprennent un axe de recherche amont en apprentissage statistique (machine learning) et des applications cliniques dans le domaine des systèmes d’aide au diagnostic pour la neuroimagerie et l’imagerie du cancer.

Carole LARTIZIENCREATIS TR 15 : Quel avenir pour le deep learning en imagerie médicale ?

Charlotte Rivière est maitre de conférences au sein de l’équipe biophysique de l’iLM depuis 2006. Elle travaille actuellement principalement sur des projets pluridisciplinaires permettant d’analyser les cellules grâce aux outils issus de la physique et de mieux comprendre le rôle de la mécanique dans les processus de progression tumorale. Elle développe notamment des microsystèmes pour analyser le comportement cellulaire dans des environnements contrôlés, modélisant le microenvironnement tumoral.

Charlotte RIVIEREUNIV. LYON-1 - ILM TR 12 : Mécanobiologie et contrôle de l’environnement cellulaire : applications pour la caractérisation des tumeurs

Jean-Paul Rieu est professeur à l’Université Lyon-1. Il dirige l’équipe Biophysique au sein de l’iLM qui travaille sur la mécanique des sphéroïdes de cellules embryonnaires ou tumorales, la régulation de la motilité cellulaire, la lubrification articulaire. Il développe des protocoles de mesure ou de contrôle des forces mécaniques tels que la microscopie à force atomique (AFM), de force de traction (TFM), ou d’autres dispositifs microfluidiques de contrôle du microenvironnement cellulaire.

Jean-Paul RIEUUNIV. LYON-1 - ILM TR 12 : Mécanobiologie et contrôle de l’environnement cellulaire : applications pour la caractérisation des tumeurs


Dr le Gros is a veterinarian specialized in immunology, microbiology and poultry science. He is senior project leader for avian vaccines within Boehringer Ingelheim AH. He developed a full range of modified live and killed adjuvanted vaccines for poultry including recently an innovative presentati*on as multidoses effervescent tablets for oral and spray application routes. He was also leader in the development of Vaxxitek HVT+IBD still number one vaccine in worldwide sales for poultry in 2017. Its route of application is the in ovo injection route, another peculiar route specific to avian vaccines for mass administration?

François-Xavier LE GROSBOEHRINGER INGELHEIM ANIMAL HEALTH TR 20 : Quelles spécificités des formulations et systèmes d’administration en santé animale ?

PhD, HDR, Chercheur CNRS Institut des Sciences Analytiques, Lyon. Activités de recherche centrées sur l’identification et l’optimisation d’inhibiteurs de protéine. Intérêt pour la Chemical Biology et le Drug Design. Expertise forte sur le criblage de fragments sur protéine, les méthodes de fragment-based-drug design ainsi que la RMN comme technique de criblage et technique structurale.

Isabelle KRIMMISA - CNRS TR 19 : Nouvelles technologies de criblage pour identifier des hits/leads dans les banques de molécules

Christophe Marquette, docteur de spécialité biochimie (1999), a intégré le CNRS en 2001. Actuellement Directeur de Recherche et Directeur Adjoint de l'ICBMS, où il mène des recherches sur les interactions biologie/surface et l’impression 3D de cellules vivantes. Depuis 1998, il est auteur de plus de 115 articles scientifiques, 13 chapitres de livre, 7 brevets et plus de 100 communications. Christophe Marquette est également fondateur de l’entreprise AXO Science et de la Plateforme technologique Innovante 3d.FAB

Christophe A. MARQUETTEUNIV. LYON-1 - CNRS TR 18 : Impression 3D : impact sur le prototypage, la petite série et la personnalisation des dispositifs médicaux

Yves Morel a débuté sa carrière pendant 12 ans dans le domaine des systèmes d’information pour différents secteurs. Rejoignant Medtronic en 2010, il est actuellement responsable du marketing pour la division Coronary and Structural Heart au sein du groupe Cardiovasculaire. Il occupe également des responsabilités dans le développement stratégique de l’innovation et dans la mise en œuvre de la vision 2022 de Medtronic France. Il représente l’innovation au sein du comité stratégique de la société Medtronic.

Yves MOREL MEDTRONIC TR 17 : Dispositifs médicaux invasifs (stents, prothèses, cathéters) : vers l’intelligence et la fonctionnalisation


OBJECTIFS Mettre en évidence les défis technologiques, scientifiques et médicaux à relever par les acteurs du pôle pour en renforcer la compétitivité. Faire émerger les collaborations et partenariats permettant de répondre à ces problématiques. Identifier et prioriser des actions fédératrices à engager en matière de développements technologiques, scientifiques, cliniques et industriels.

TABLES RONDES DE BRAINSTORMINGMéthodologie


1 / TOUR DE TABLE : présentation succinte de chaque participant (10 à 20 par table, grands groupes/PME/start-up, académiques et cliniciens).

2 / PRÉSENTATION DU DOMAINE PAR L’ANIMATEUR : état de l’art, contexte/problématiques et enjeux.

1 FACILITATEUR, équipe Lyonbiopôle et structures partenaires

Fonction : faciliter la compréhension des objectifs, du déroulement et des règles du jeu, contrôler le temps et le respect des principes de l’exercice.

1 ANIMATEUR, expert du domaineFonction : présenter le contexte et les principaux défis du thème en introduction puis animer le groupe, challenger les participants, reformuler les propositions et synthétiser les actions clés identifiées.

1 SECRÉTAIRE DE SÉANCE (à désigner en début de séance)

Fonction : prendre des notes synthétiques des débats (convergences/divergences, conflits de fond, facteurs critiques évoqués,

autres points particuliers).

10h15 - 10h45

TABLES RONDESComposition & introduction


Enjeu A

Enjeu B

Enjeu C

TABLES RONDESDéfinition de 3 enjeux prioritaires

3 / RÉACTION ET DISCUSSION DES PARTICIPANTS : sur l’état de l’art et les enjeux du domaine présentés en introduction par l’animateur.

4 / IDENTIFICATION COLLECTIVE DE 3 ENJEUX PRIORITAIRES sur lesquels travailler durant la table ronde.

10h45 - 11h10


11h10 - 11h25 Chaque sous-groupe à 15 minutes pour formuler sur post-it ses propositions d’actions en réponse à l’un des enjeux (1 seule action écrite par post-it).

11h25 - 11h40 Les sous-groupes se décalent pour passer à un autre enjeu et incrémentent la liste des solutions (post-it) proposées par le sous-groupe précédent.

11h40 - 11h55 Les sous-groupes se décalent à nouveau et incrémentent la liste des solutions (post-it) proposées par les sous-groupes précédents.

Enjeu A

Action A1

Action A2

Action A3

Action A4

Action A5

Action A6

Enjeu B

Action B1

Action B2

Action B3

Action B4

Action B5

Action B6

TABLES RONDESIdentification des solutions

5 / LES ENJEUX (A,B,C) SONT DISPOSÉS DANS 3 COINS DISTINCTS DE LA SALLE : les participants se répartissent en 3 sous-groupes qui vont réfléchir successivement aux solutions/actions à apporter à chaque enjeu.

11h10 - 11h55

Enjeu C

Action C1 ActionC4

Action C2

Action C3

ActionC5

ActionC6


Enjeu A

Enjeu B

Enjeu C

TABLES RONDESQualification des actions

6 / Le 3ème sous-groupe de chaque enjeu à 10 minutes pour POSER LES PRINCIPALES ACTIONS PROPOSÉES (= les post-it) sur le graphique affiché dans la salle selon deux paramètres : > leur potentiel, > leur durée de mise en oeuvre.

11h55 - 12h05

Action A1

Action A2

Action A3

Action A4

Action A5

Action A6

Action B3

Action B1

Action B2

Action B4

Action B5

Action B6Action C1

Action C2

Action C3

Action C4Action C5

Action C6

ÉLEV

ÉM

OYE

NFA

IBLE

COURT TERME MOYEN TERME LONG TERME

Durée de mise en oeuvre

Pote

ntie

l


TABLES RONDESDiscussion générale

7 / L’ANIMATEUR DISCUTE AVEC LES PARTICIPANTS DES ACTIONS PROPOSÉES pour chacun des 3 enjeux et de leur positionnement. L’animateur synthétise et conclut les débats.

12h05 - 12h45

Action A1

Action A2

Action A3

Action A4

Action A5

Action A6

Action B3

Action B1

Action B2

Action B4

Action B5

Action B6Action C1

Action C2

Action C3

Action C4Action C5

Action C6

ÉLEV

ÉM

OYE

NFA

IBLE

COURT TERME MOYEN LONG TERME

Durée de mise en oeuvre

Pote

ntie

l

? !


Conférence d’ouverture14:00 - 15:00RESTITUTIONS DES TRAVAUX DES TABLES RONDESSalles parallèles


14h00-14h30Restitution des

travaux des tables rondes impaires

14h30-15h00 Restitution des

travaux des tables rondes paires

TR1 TR3 TR5 TR7 TR9 TR11 TR15 TR17 TR19

TR2 TR4 TR6 TR8 TR10 TR12 TR14 TR18 TR20

TABLES RONDESRestitutions des travaux

RESTITUTIONS ORALES DE 30 MIN RÉALISÉES DANS CHAQUE SALLE DE TABLE RONDE par les animateurs afin d’expliciter les actions/solutions imaginées lors des brainstorming. Les participants de la Journée Collaborative choisissent librement les restitutions auxquelles assister.

14h00 - 15h00

Voir la liste des thématiques sur les pages 9 et 10.


Conférence d’ouverture15:00 - 17:15BLUESKY MEETINGSalle du Conseil

15:00 - Présentation de Boehringer Ingelheim par Julie Edwards, Contract Negociator and Alliance Manager Europe 15:15 - Session 1 : Offres technologiques innovantes 16:15 - Session 2 : Idées de projets R&D ouverts aux partenariats


Since 1885 we have been on a path that has consistently delivered innovation excellence. Now, more than 130 years later, we continue to innovate, motivated by patients in need, driven by science and inspired by our growing global community of innovation partners, to discover and develop exceptional medicines that set new and advanced treatment standards and transform patients’ lives.

Our Partnering Interests

Our partnering priorities encompass opportunities across the entire research and development value chain in the following areas:

CardioMetabolic diseases: liver diseases, diabetic retinopathy (DME, DR, nPDR), chronic kidney diseases, novel obesity treatments achieving weight loss > 10%, breakthrough treatments for type 2 diabetes, pancreas recovery options

Cancer Research & Cancer Immunology: cancer cell-directed therapies and immune cell-directed therapies

CNS diseases: Alzheimer’s disease, schizophrenia, depression and impulse control disorders

Immunology: Crohn’s disease, ulcerative colitis and inflammatory skin diseases

Respiratory diseases: idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome and cystic fibrosis

Research Beyond Borders: regenerative medicine, microbiome and gene therapy

Technologies: platform and enabling technologies with the potential to enhance our NCE capabilities or support our therapeutic areas; technologies for rapid generation of probes/tools for the validation of new therapeutic concepts, or to accelerate timelines; targeted intracellular delivery technologies; companion diagnostics.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in…

Meet Boehringer Ingelheim at the Lyonbiopole partnering day

Representing Boehringer Ingelheim’s Business Development and Licensing team at Lyonbiopole, Julie Edwards is responsible for leading contract negotiations and managing alliances that support the Company’s scientific and business development objectives. Previously Julie was Head, Research Beyond Borders Project Office and Strategic Partnering, where she facilitated the development and implementation of project proposals through external sources of innovation.

Working together for better health

Innovation @ Boehringer Ingelheim


Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Operating globally and headquartered in Germany, our focus is on researching, developing,

manufacturing and marketing new medications of high therapeutic value. In 2015, Boehringer Ingelheim achieved net sales of 12 billion euros investing 24% per cent of this in research and

development of new medicines*. With a robust research and development portfolio of more than 100 projects, a progressive innovation strategy and an increased emphasis on external

partnerships, we are on a well-defined path for long-term innovation-led performance.

*2016 net prescription medicine sales

For more information visit: www.boehringer-ingelheim.com/partnering

BI_Advertorial_NH05.indd All Pages 19/09/2017 09:52


Since 1885 we have been on a path that has consistently delivered innovation excellence. Now, more than 130 years later, we continue to innovate, motivated by patients in need, driven by science and inspired by our growing global community of innovation partners, to discover and develop exceptional medicines that set new and advanced treatment standards and transform patients’ lives.

Our Partnering Interests

Our partnering priorities encompass opportunities across the entire research and development value chain in the following areas:

CardioMetabolic diseases: liver diseases, diabetic retinopathy (DME, DR, nPDR), chronic kidney diseases, novel obesity treatments achieving weight loss > 10%, breakthrough treatments for type 2 diabetes, pancreas recovery options

Cancer Research & Cancer Immunology: cancer cell-directed therapies and immune cell-directed therapies

CNS diseases: Alzheimer’s disease, schizophrenia, depression and impulse control disorders

Immunology: Crohn’s disease, ulcerative colitis and inflammatory skin diseases

Respiratory diseases: idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome and cystic fibrosis

Research Beyond Borders: regenerative medicine, microbiome and gene therapy

Technologies: platform and enabling technologies with the potential to enhance our NCE capabilities or support our therapeutic areas; technologies for rapid generation of probes/tools for the validation of new therapeutic concepts, or to accelerate timelines; targeted intracellular delivery technologies; companion diagnostics.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in…

Meet Boehringer Ingelheim at the Lyonbiopole partnering day

Representing Boehringer Ingelheim’s Business Development and Licensing team at Lyonbiopole, Julie Edwards is responsible for leading contract negotiations and managing alliances that support the Company’s scientific and business development objectives. Previously Julie was Head, Research Beyond Borders Project Office and Strategic Partnering, where she facilitated the development and implementation of project proposals through external sources of innovation.


Innovation @ Boehringer Ingelheim


Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Operating globally and headquartered in Germany, our focus is on researching, developing,

manufacturing and marketing new medications of high therapeutic value. In 2015, Boehringer Ingelheim achieved net sales of 12 billion euros investing 24% per cent of this in research and

development of new medicines*. With a robust research and development portfolio of more than 100 projects, a progressive innovation strategy and an increased emphasis on external

partnerships, we are on a well-defined path for long-term innovation-led performance.

*2016 net prescription medicine sales

For more information visit: www.boehringer-ingelheim.com/partnering

BI_Advertorial_NH05.indd All Pages 19/09/2017 09:52


HUMAN MEDICINEIN VITRO DIAGNOSTIC MEDICAL DEVICES

OFFRES TECHNOLOGIQUES INNOVANTES

3C HEALTHMedical devices & services for cardiovascular diseases Guillaume BLIVET - CEO

P. 28

IDÉES DE PROJETS R&D OUVERTS AUX PARTENARIATS

BARIATRIC EATING BEHAVIOUR Observational and interventional exploration of the evolution eating behavior in patients who underwent bariatric surgery (weight loss) Anestis DOUGKAS - Research Scientist in Nutrition, Health and Eating Behaviour/INSTITUT PAUL BOCUSE

P. 48

15:15 - SESSION 1 16:15 - SESSION 2

P. 30 ADJUVATIS I-Particles technology, a safe-by-design, fully metabolizable drug delivery system Charlotte PRIMARD - CEO

P. 32 ANTINEO Development of in vitro and vivo of tumor models resistant to treatments Elsa KRESS - Study Director & Business Development Manager

P. 34 BIOMECA BioMeca Pascale MILANI - Co-founder & CTO

P. 36 ECRINS THERAPEUTICS Tubulin, not only for the oncology... Emmanuelle FUGIER GARREL - Sales Manager

P. 38 FASTEESH FasTeesh : a technology able to brush your teeth in 10 seconds Christophe CADOT - Co-Founder & CTO

P. 40 HOLI Wearable device and artificial intelligence to detect respiratory diseases at early stages (sleep apnea) Grégoire GERARD - Chairman & Founder

P. 42 SIGNIA THERAPEUTICS Breakthrough Solution for Respiratory Infections - A Novel and Proprietary Technology for Drug RepurposingMichel COUSINEAU - President

P. 44 SYNTHELIS From Gene to StructureSafia EZZINE - Business development manager

P. 46 VEINSOUND Innovative therapeutic platform development for fully extracorporeal varicose vein treatmentThomas CHARREL - CTO

BIOPRINTINK3D Bioprinting of functional living tissues for R&D and medical use Caroline DURAND - Project leader/LABSKIN CREATIONS

P. 52

HO & MEHospital and me Charly GADUEL - Manager of the health domain/LOJELIS

P. 56

MECACHIPSToward more physiological in vitro cell culture Camille MIGDAL - Researcher/CEA

P. 58

MIMESISA novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses Nicolas GUYON-GELLIN - VP Corporate Development & Strategy/ENYO PHARMA

P. 60

PACLIO PAired Cell Lines In Oncology Cédric CHAVEROUX - Chargé de recherche CNRS, Groupe S. Manié/CLB

P. 62

QDDP In vitro diagnostic platform for non-invasive biomarker quantification Roger MALLOL - Scientific project coordinator/ICIQ

P. 64

SINNOTEST Predictive medicine for chronic inflammatory disease Pierre-Marie GIROD-ROUX - CEO/SINNOVIAL

P. 66

BIOACTIVE COATINGSBioactive coatings in multiple well cell culture plates Catherine PICART - Professeur des Universités/INPG

P. 50

FEALINXUltimate IT Solution for «in silico» medicine Bruno VIRIEUX - Deputy CEO/FEALINX

P. 54


3 C H E A LT H

CONTACT BLIVET Guillaume Position: CEOPhone: +33 (0)46 75 93 52 66Email: [email protected]

TECHNOLOGY OFFER

MEDICAL DEVICES & SERVICES FOR CARDIOVASCULAR DISEASES

Business model: Mixed model - service provider and product developerStrategic area of application: Medical technologiesApplication fields: Cardiovascular diseases

SIZE OF TARGETED MARKET

POSITION COMPARED TO COMPETITION

Our targeted market is : health professionals and particularly doctors concerned with the prevention and follow-up of patients at risk at cardiovascular level ; Hospitals, nursing homes, hypertension centers, payers (social security, mutual insurance, insurance), occupational medicine and check-ups (especially in Asia), clinical research for evaluating Arterial stiffness and cardiovascular risk (institutional research, CRO, pharmaceutical industries, etc.).

Arterial stiffness is a way to predict cardiovascular events. Arterial stiffness is measured by Pulse Wave Velocity (PWV). We combine a market product position including a golstandard PWV measurement (precision & quality of the measure) and a ease of access and use. Because today the market is composed of golstandard devices noteasy to use or devices with a derived measures of PWV (no golstandard). So we observed there was a place for an innovative, non-invasive, practical and user-friendly PWV measurement device. That is what we do. Our device is connected so we we download and manage the data into the cloud. We have also added other kind of measures with other connected devices (sphygmomanometer, oxymeter) and a remote monitoring tool for doctors and patients.

INNOVATIVE ASSETSWe have a patent on the PWV measurement and a know how in IT, signal processing, optic, electronic, public health, disease management, emote monitoring and eHealth.

DESCRIPTION OF THE INNOVATIVE TECHNOLOGY OFFER AND APPLICATION TARGETED

Our technology is designated for cardiovascular risk prevention. It allows for innovative, non invasive, practical and user friendly evaluation of arterial stiffness (especially central pressure and pulse wave velocity) and consequent potential risk of a cardiovascular event. These measurement tools lean on comprehensive and high-performing software assuring monitoring of the patients.

Pulse Wave Velocity (PWV) is a parameter validated for its correlative accuracy in numerous cardiovascular pathologies, that has been neglected due to its operating difficulties. Thanks to our efforts, this high-precision parameter allowing for actual as well as predictive evaluation of the patient’s state has become largely more accessible to clinical medical practice. We used new technologies both at sensors and IT processing of data levels. Very importantly, the ergonomics of new devices have also been improved . Great number of international scientific publications demonstrate the importance of PWV measurement as a prevailing method in prognostic and predictive values in many cardiovascular pathologies.

BLUESKY MEETING SESSION 1 : OFFRES TECHNOLOGIQUES INNOVANTES

OTHER INFORMATION3C health (Connect, Check & Care for Health), is an innovative MedTech & eHealth company with an expertise in the field of connected medical technologies. We offer solutions to health professionals aiming for better detection, prevention and overall health improvement methods.


.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

etoN s

ILLUSTRATIONLegend: PWV measurment device

Copyright: 3C health

PARTNERSHIP TARGETEDProduct co-development


A D J U V A T I SCONTACT PRIMARD Charlotte Position: CEOPhone: +33 (0)4 72 72 26 56Email: [email protected]

TECHNOLOGY OFFER

I-PARTICLES TECHNOLOGY, A SAFE-BY-DESIGN, FULLY META-BOLIZABLE DRUG DELIVERY SYSTEM

Business model: Mixed model - service provider and product developerStrategic area of application: Human medicinesApplication fields: Dermocosmetics, Oncology



Drug Delivery Systems (DDS) are used for many applications (cancer, vaccines, ...) and covers many technologies (nanotechnologies, implantable systems). This market is segmented based on route ofadministration, technology, and region. The world DDS market generated $122.3bn in 2012, (Drug Delivery Technologies May 2013) and $1,179.20 Billion in 2016 (markets&markets, Jan. 2017). In 2001, 15% of pharmaceuticals’ R&D budgets were devoted to the integration of new drug delivery systems.

Adjuvatis is nowadays focused on one main technology, perfectly mastered. Made of poly(lactic acid) polymer, our particles are uniquely surfactant free as token of safety. Contrary to the technologies based on liposomes, our i-Particles are very stable without any post-production treatment. Hence, the i-Particles technology and the formulations with your active pharmaceutical ingredient has a high potential in clinical development. In addition to its service activities, Adjuvatis develops its own products based on i-Particles which, in addition to ten years of research and development, ensures strong track record on their biodistribution, safety, efficacy both in vitro and in vivo. This is why Adjuvatis is particularly offering its services in cases of non-water soluble drugs or toxic drugs. Furthermore the i-Particles are specially adapted for drug delivery through skin, for trans-mucosal transport or for targeting liver and immune organs.

INNOVATIVE ASSETS10 years of R&D at international level, two patents and more than 25 publications ensure a high degree of mastery of our technology. It was evaluated for many applications (dermatology, infectious disease, cancer). To ensure a proper clinical development of formulations with our i-Particles, our technology meets the needs in terms of:- Versatility. Hydrophobic and hydrophilic drugs can be formulated by encapsulation and/or association in surface.- Post-formulation. The i-Particles were formulated on hydrogels, associated with fibers, systemically injected or favouring trans-mucosal delivery.- Safety: our safe-by-design production method is uniquely surfactant and stabilizer-free, and without any residual solvents.- Industrialization. High stability of the particles (more than 2 years in solution), no lyophilisation is required, homogeneous particles and high batch-to-batch reproducibility, high yield of production 90%.


OTHER INFORMATIONWhat for a drug delivery system may be required ?Technical requirements:- To solubilize hydrophobic drugs,- For targeting delivery to the organs/cells of interest- For detoxification and reducing risk profile- For controlled and sustained deliveryStrategic development:- Increasing drug efficacy same components than concurrent, better efficacy- Reducing costs- Providing patient-friendly dosage forms.- For extension of product life cycle (novel way of delivery, new markets, etc)


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

ILLUSTRATIONLegend: i-Particles

Copyright: Adjuvatis


Adjuvatis’ goal is to offer the i-Particles technology to overcome the difficulties associated with the development of new medicines (non-water solubility, degradation, toxicity, etc), and to offer the pharmaceutical industries new formulations favoring product line extension (improving drug efficacy, providing patient-friendly dosage forms, gaining new markets as paediatrics, etc). Our biodegradable and fully metabolizable particles are made of poly(lactic acid), a FDA agreed polymer. Uniquely we used a surfactant free nanoprecipitation process, which permits the elaboration of reproducible and homogeneous particles in the 200 nm range. This method allows the shear-free encapsulation of active pharmaceutical ingredients (API) as immune-modulators, fluorophores, antiviral, anticancer drugs, antibiotics or antioxydants. Our i-Particles technology is particularly adapted to the poor water solubility issue, which is the most significant barrier limiting drug development. Adjuvatis offers to solubilize hydrophobic drugs by their encapsulation into biodegradable i-Particles. This service of formulation includes the definition of specifications adapted to the product and its future application, formulations development and characterization in terms of size, homogeneity, drug loading, stability studies, etc, and eventually biological evaluations. Our team is composed of two senior scientists, part time, one PhD scientist full time, one Chemical Engineer and two juniors.

PARTNERSHIP TARGETED

Adjuvatis is a key partner to support innovative drug development and seeks for contract manufacturing.


A N T I N E O

CONTACT KRESS Elsa Position: Study Director and Business Development ManagerPhone: +33 (0)4 26 68 82 01Email: [email protected]

TECHNOLOGY OFFER

DEVELOPMENT OF IN VITRO AND VIVO OF TUMOR MODELS RESISTANT TO TREATMENTS

Business model: Service provider - CROStrategic area of application: Human medicinesApplication fields: Oncology



Antineo is currently focusing on the European market. We provide services to pharmaceutical companies, biotechs and academic researchers.

Acquired resistance to therapy is a major issue in oncology. The resistance mechanisms are poorly understood and represent a major limitation for the development of novel therapies by biotechs and pharmas. While Antineo’s competitors often propose sensitive and resistant models, these are in most cases spontaneously resistant models with unknown mechanisms of resistance. Antineo has chosen an original approach with the development of models with acquired resistance to gold standard treatments. We currently have a panel of in-house developed resistant models and also develop custom models for customers. These models are well characterized both in terms of sensitivity to various compounds and in terms of potential mechanisms of resistance. Our customers thus have the possibility to determine the antitumor activity of their agents in paired, sensitive and resistant, models.


A large number of cancer patients will initially respond to medical therapy before suffering relapse with resistant disease. In order to develop novel active and original therapies it is therefore necessary to test novel agents in clinically relevant resistance models. Our models are developed to be resistant to gold standard therapies, which reflect the clinical situation in which novel agents will be analyzed in the scope of phase II clinical trials. Importantly we perform molecular and phenotypic characterization of our resistance models in comparison to the parental sensitive models. While all preclinical models suffer from limitations, our approach provides our customers with a unique opportunity to evaluate their agents in models which are closely related to clinical situations of resistance.So far, Antineo has obtained models resistant to chemotherapy and/or immunotherapy. Those models, CDX or syngeneic, are representative of various indications. We therefore have the know-how to develop, in the frame of a consortium agreement, a variety of resistant models.INNOVATIVE ASSETS

The resistance models proposed by Antineo, as well as the possibility to produce custom-made new resistance models, are based on a unique know-how. The process is not patented but is complex to reproduce and Antineo’s commercial interests are protected by a non-diffusion policy.


OTHER INFORMATIONAntineo aims to accompany customers in the preclinical development of novel anticancer agents. The expertise and experience of Antineo will support customers in the choice of optimal or the development of customized models as well as the identification of the most relevant conventional treatments for drug comparison and/or combination studies. We provide strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications and the therapeutic landscape in specific indications.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


We would like to integrate and offer our expertise within public funded projects such as PoC, EuroStars or FUI call for projects, for co-development with R&D teams developing new cancer treatments, either in combination or in competition with reference drugs. Antineo’s partners will benefit from high-end model development technology, years of experience and top-level expertise in several oncology diseases for the development and the use of relevant and reliable pre-clinical resistance models.


B I O M E C A ®

CONTACT Pascale MILANI Position: CTO and co-founderPhone: +33 (0)4 72 72 89 35Email: [email protected]

TECHNOLOGY OFFER

BIOMECABusiness model: Mixed model : service provider and product developer Strategic area of application: Medical technologiesApplication fields: Cardiovascular diseases, Dermocosmetics, Oncology



BioMeca positions itself in the international market of high-resolution biophysical measurements and structural analysis for life science companies and academic research. As confirmed by metrics (PubMed), Atomic Force Microscopy analysis (AFM) is a field of growing importance that will play a major role in the years to come. Biological and mechanical aspects are combined together so as to move towards the global modelling of cells, tissues and organs.

Understanding the physical mechanisms involved in complex biological processes is one of the greatest challenges of biology. The numerous studies conducted over the past few years show increasing interest in the study of mechanical properties of cells. It is particularly interesting in field of medicine since it could help increase our understanding of diseases such as cancers. The development of cancer is not only biochemical and genetic. Abnormal mechanical constraints and modified physical properties, activating tumor biomolecules, appear to be potential components of tumor growth and invasiveness. The key advantage of BioMeca services is the use of AFM technology for in-vivo analysis, and the possibility to identify the 3D dynamic characteristics of biological materials. BioMeca expertise is the keystone of the competitive advantage of the company. The commercial strategy is based on helping to interpret the biological data collected.

INNOVATIVE ASSETSAFM is a technique allowing to visualize the three-dimensional morphology of the surface of a material with nanometric resolution and to map out some of its properties (adhesive, mechanical, magnetic, electrical, etc.). The principle of AFM is based on the interaction between the sample surface and a nanometric tip fixedunder a cantilever. The tip scans over the surface and follows the topography of the sample, producing a three-dimensional image of the material. BioMeca expertise, the result of 15 years of research in the field, now enables to use AFM technology for the in vivo analysis of biological materials, what life science companies have been waiting for 20 years.

DESCRIPTION OF YOUR INNOVATIVE TECHNOLOGY OFFER AND APPLICATION TARGETED

AFM technology applied to living things and more specifically to cancer is going to allow the emergence of a whole category of new markers. It opens new horizons in terms of diagnosis and prognosis, and possibly in terms of theranostics, especially since personalized medicine will be a major issue in the years to come. BioMeca offers an automated service that can address many of the problems faced by practitioners. As an example, we known that the biophysical features of the stroma in pancreatic cancer varies depending on the stage. Our innovative approach to Live Force Tomography (LFA) allows us to acquire high-resolution images of the mechanical properties in 3D of the tissues and the cancer cells. As a result, we can provide access to the physical characteristics of tumors and their potential of invasiveness and identify «mechano-markers».



BioMeca would like to create partnerships with public and/or private research laboratories/units in order to develop and expand its R&D programs.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

........................................................................................................................


E C R I N S T H E R A P E U T I C S

CONTACT FUGIER GARREL Emmanuelle Position: Sales ManagerPhone: +33 (0)4 76 54 95 67 Email: [email protected]

TECHNOLOGY OFFER

TUBULIN, NOT ONLY FOR THE ONCOLOGY...Business model: Mixed model : service provider and product developerStrategic area of application: Human MedicineApplication fields: Neurology, Oncology



Our message is directed to all the actors of the drug-discovery: Biotech, Academic laboratories or Big Pharma. We would like to target all the research teams who develop drug candidates, in the areas of virology, cell trafficking but mainly Oncology and Neurology.

We are the only ones who propose this expertise around the cytoskeleton and its effectors. An American company based in California, offers products in connection with the cytoskeleton, but not the services. Our objective is to offer our expertise and our know-how to help drug-hunters to identify their target or to target a specific microtubules associated protein.

INNOVATIVE ASSETSOur innovative technology is based on our know-how that let us purify pure native tubulin, the key component of the microtubules. We used this protein in a polymerization test, to screen drug candidates and determine if they target tubulin or not. As a major component of the mitotic spindle which allows cell division, tubulin is a well-known target in oncology, and numerous approved drugs for cancer therapy target tubulin.Ecrins therapeutics has realized a screening of 5000 molecules from an academic library and has identified a drug candidate, ET-D5 which is now very close to its first clinical trial. To select bioactive molecules with anti-mitotic activity and an original target, we screened molecules on cells and the bioactive ones were then the in tubulin polymerization assay to eliminate anti-tubulin molecules.

DESCRIPTION OF YOUR INNOVATIVE TECHNOLOGY OFFER AND APPLICATION TARGETEDMicrotubules are critical components of the cytoskeleton and play several major roles in cells. Tubulin is a well-know target in oncology as they are of particular importance during mitosis, when they form a mitotic spindle, a bipolar array of microtubules and microtubule-binding proteins with chromosomes in the middle. Microtubules are composed of tubulin, a heterodimer of α; and β ; subunits with an apparent molecular mass of 110 kDa. In the presence of GTP, the α; and β; tubulin heterodimers can polymerize (in-vivo and in-vitro) to form microtubules. Microtubules have a crucial role in facilitating long-distance transport of both proteins and organelles. In neurons, impaired fast axonal transport (FAT) is a hallmarks of tautopathies as Alzheimer disease.



We would like to found collaborators to help them in the screening of their drug candidates in the area of neurodegenerative diseases. With our expertise in screening and in cytoskeleton, we are looking for partners who are specialized in neurology, to discover and develop together new targets among the microtubules-associated proteins, and more particularly for Alzheimer disease.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


F A S T E E S H

CONTACT CADOT Christophe Position: Co-Founder & CTOPhone: +33 (0)7 83 47 71 58Email: [email protected]

TECHNOLOGY OFFER

FASTEESH : A TECHNOLOGY ABLE TO BRUSH YOUR TEETH IN 10 SECONDS

Business model: Product developer - Other healthStrategic area of application: Medical technologiesApplication fields: Geriatrics, Other



We have targeted 2 different markets:- Elderly: 1.5M people in France- Mass market: 39 billion $ for dental care (including toothbrush, toothpaste, etc. in the whole world)

We have developed a new tool able to replace the toothbrush.Our main competitive advantage is the reduction of the working time from 2 minutes to 10 seconds with the same efficacy. 3 others startups are developing a similar product, but for different markets. Regarding them, our main advantage is we work on a medical device with an efficacy proved.

INNOVATIVE ASSETS- 2 pending patents (+1 more before 2018).- Technical complexity to manufacture the product

DESCRIPTION OF THE INNOVATIVE TECHNOLOGY OFFER AND APPLICATION TARGETEDWe have developed an innovative product able to brush your teeth in 10 seconds efficiently by brushing them simultaneously. It works with a consumable which needs to be replaced 2 times a year. We targeted first elderly people. Another application targeted is the ability to clean dentures.



We are looking for various kind of partners:- Development and use of in vitro and in vivo characterization tests - Socio-economic study of oral hygiene in the elderly population- Development of a suitable toothpaste- Manufacturers or distributors to be able to get a fast market access (particularly for the mass market).

OTHER INFORMATIONOur current team is composed of- 1 CEO- 1 CTO (PhD)- 1 dentist (KOL) + 1 doctor specialized on our first market- 1 expert in communications strategyWe have several proofs of interest from our partners and from our future customers. In addition to that, we have successfully managed in vitro tests 1 year ago and we are launching tests with prototypes in October 2017.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

........................................................................................................................


H O L I

CONTACT GERARD Grégoire Position: Chairman & FounderPhone: +33 (0)6 64 33 55 39Email: [email protected]

TECHNOLOGY OFFER

WEARABLE DEVICE AND ARTIFICIAL INTELLIGENCE TO DETECT RESPIRATORY DISEASES AT EARLY STAGES (SLEEP APNEA)

Business model: Product developer - Other healthStrategic area of application: Medical technologiesApplication fields: Cardiovascular diseases



The sleep apnea market is estimated to 10B$ in 2017 and is expected to grow to 20B$ by 2020. The global rate of the population that suffers from sleep apnea is estimated to 5-10% but can reach 30% if mild patients are taken into account (scientific studies have proven that treating sleep apnea at early stages increase patient life expectancy and decrease costs for the society). 80% of the patients still remain undiagnosed while the sleep apnea increases dramatically the risks to suffer from hypertension, diabete-II, heart failure and car accidents. Every year, sleep apnea costs more than 100B$ to the USA.

The present solutions to diagnose sleep apnea are not easily accessible by the patients (it takes 6m to 1y to be diagnosed by a specialist), are expensive (diagnostic tools cost up to 20k$ and are not accessible by emerging markets or non-specialists) and are not automated (the reading of the results takes 20 minutes per patient and very few specialists are capable of doing it).

Holi addresses the 2 main challenges of the sleep apnea market :> How to decrease the level of undiagnosed people?> How to decrease the cost of undiagnosed patient for the society without expensive diagnosis tools?> How to control the efficacy of the treatment one the patient is treated?

INNOVATIVE ASSETSHoli set 3 patents and combines multiple expertises.The innovation comes from the combination of a complete processing chain :> Innovative screening tool : Holi has successfully deployed a smartphone application that enables to screen large population without anything else than using the microphone to track specific sleep apnea breathing patterns> Innovative sensor and signal processing : Holi is able to track vital signals with low-cost electronic components (accelerometers) placed on the body> Advanced algorithm based on machine learning : By using machine learning technologies, each result is based on millions of patients data (and not only the patient data only)> Innovative form-factor : Holi’s solution can be used by the patient or non-specialist physician without any specific training


Holi brings innovative solutions to detect sleep apnea risks at very early stages among large population. Thanks to machine learning technologies and artificial intelligence, Holi democratizes the sleep apnea tests while keeping the same level of accuracy than present solutions and promotes new service to follow patient treatment adherence at home without any physician assistance.

OTHER INFORMATIONHoli is conducting clinical trials with the most reknown sleep medicine specialists and has already proven the accuracy of its solutions.


Holi’s offer is composed of :> Snoremeter : An App used by thousands of people every month to evaluate their snoring (80% of sleep apnea patients suffer from snoring) and to detect sleep apnea risks. > SleepDoctor : An easy-to-use device placed on the chest to monitor patient vital signals while he/she’s sleeping. This offer is directly to consumers (online shopping) to services-oriented pharmacies and to non-specialist physicians in the emerging markets.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


Holi is looking for :> medical partnership to increase its clinical expertise> business partnerships to explore new markets for which its technologies could be advantageously a benefit (BPCO)> business partnerships to expend its offers in the emerging markets.


S I G N I A T H E R A P E U T I C S

CONTACT COUSINEAU Michel Position: PresidentPhone: +33 (0)6 70 31 46 70Email: [email protected]

TECHNOLOGY OFFER

BREAKTHROUGH SOLUTION FOR RESPIRATORY INFECTIONS - A NOVEL AND PROPRIETARY TECHNOLOGY FOR DRUG REPURPOSING

Business model: Product developer - PharmaceuticalsStrategic area of application: Human medicinesApplication fields: Infectious diseases



In an effort to treat these Acute respiratory tract infections, consumers spend $2-3 B each year. The therapeutics market for Influenza is estimated to grow from nearly $1 B in 2014 to nearly $1.3 B in 2018, with an expected annual growth rate of 8% for the period of 2014-2018. The therapeutics market for Respiratory Syncytial Virus (RVS; bronchiolitis) was nearly $0.65 B in 2014 and is estimated around $2.3 B in 2024, with an estimated annual growth rate of 29.9% for the period of 2014-2024.

The novel drug-discovery strategy proposed by Signia Therapeutics presents 3 obvious advantages: 1- by targeting host cellular pathways instead of viral proteins, the Company should achieve broad-spectrum antiviral efficacy & minimize the risk of emergence of drug-resistant viruses, which is a serious problem with current antivirals against error-prone RNA viruses; 2- Signia’s versatile platform can further be expanded for the identification of active molecules against other classes of viruses as well as intracellular bacteria or parasites &; 3- the innovative strategy for the identification of new indications for existing drugs provides a more rapid & cost-effective drug development alternative, with important implications for rapid response outbreak preparedness. With the acquisition of know-how and technology, the constitution of its own proprietary database, the Company will quickly expand programs focused on other respiratory viruses such as RSV, hMPV and human Coronaviruses.

INNOVATIVE ASSETSProofs-of-concept were established, several FDA-approved drugs were validated for new antiviral indication & one clinical trial (FLUNEXT) will start in Dec. 2017 for the evaluation of one promising antiviral candidate in 300 Flu patients, with final results expected in 2019. This clinical trial is financed by the French Health Ministry. Other programs by Signia Therapeutics dedicated to the identification & validation of broad-spectrum antiviral compounds against Flu, RSV, hMPV and MERs-CoV. With the acquisition of know-how and technology, the constitution of its own proprietary database, Signia therapeutics will quickly expands programs and new modes of delivery, i.e. nebulization, to secure more patents and a stronger IP portfolio for products discovered from its proprietary platform.


Signia Therapeutics proposes an innovative & versatile platform for antiviral drug discovery & repositioning based on globally targeting the host cell instead of specific viral molecular determinants. The Company’s strategy is well adapted to the pathogenesis of respiratory acute infections & provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative & proprietary platform will offer the minimization of drug resistance, with significant regulatory & financial benefits compared to the time-consuming & costly process of classical de novo molecule development. The Company’s proposes a novel strategy to identify & repurpose rapidly, efficiently & at low cost already marketed drugs for new antiviral indication against one or several human respiratory viruses that could be evaluated in clinical trials and/or quickly available in response to any widespread outbreak for which the medical community & patients have limited options. Signia’s approach will offer: Significant cost & time reduction to validate


OTHER INFORMATIONAcute respiratory tract infections represent the main cause of acute diseases worldwide. Signia proposes a novel strategy to identify & repurpose rapidly, efficiently & at low cost already marketed drugs for new antiviral indication that could be evaluated in clinical trials and/or quickly available in response to any widespread outbreak for which the medical community & patients have limited options. New efficient antiviral strategies, less prone to the emergence of resistance, are necessary.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


With the advancement of its proprietary know-how, patented technology & the constitution of its own database, Signia Therapeutics will present its technology & products to pharmaceutical companies. The Company will seek licencing & partnership opportunities (including co-development) for its 3 patents for 5 repurposed drugs to treat Flu and 2 repurposed drugs to treat MERS-CoV. Signia will also seek investments to accelerate the platform development and identify more antiviral drug candidates.

clinical trial drug candidates, enable rapid transition to Ph 2 trials, shortening of response times of widespread outbreaks, rapid return on the investment for drug development to market of new antivirals & new value-added IP opportunities. Very few efficient vaccines or antiviral treatments have been reported in the medical literature to fight against these respiratory pathogens.


S Y N T H E L I S

CONTACT EZZINE Safia Position: Business development managerPhone: +33 (0)6 46 23 12 60Email: [email protected]

TECHNOLOGY OFFER

FROM GENE TO STRUCTURE

Business model: Mixed model : service provider and product developerStrategic area of application: Human medicinesApplication fields: Infectious diseases, Inflammatory diseases, Oncology



The global structural biology & molecular modeling techniques market accounted for USD 2.52 billion in 2015 and is expected to reach USD 13.1 billion by 2025. The market is predominantly driven by rise in the prevalence of chronic diseases, such as diabetes and cancer, with acquired drug resistance that exemplifies the need for new and advanced therapeutics.

Compared to competition, SYNTHELIS has based its service offer on a cell-free expression technology to quickly produce, label and purify the quantity of protein required for structural analysis. With its proprietary technology combined with a strong know-how in term of cell-free expression, SYNTHELIS is able to address projects with difficult-to express proteins and more especially membrane proteins. To manage such challenging projects, SYNTHELIS takes advantage of the cell-free system to quickly select the best construct among several through a high throughput multigene expression process. SYNTHELIS is also able to optimized in-silico a sequence to increase the solubility and/or the thermostability of a protein to bring to structure determination. Finally, SYNTHELIS has partnered with internationally renowned institutes in Grenoble and thus has access to the best state-of-the-art instruments and expertise for structural analysis.

INNOVATIVE ASSETS


The innovative technology offer of SYNTHELIS is centered around a cell-free system combined with a strong know-how to efficiently performed any structural biology project in providing rapidly enough quantity of a protein of interest in the appropriate conditions (labelling, purity, buffer…) to obtain structural data with any kind of available methods from circular dichroism to X-Ray or Neutron diffraction, NMR or cryo-electron microscopy (cryo-EM). Our offer includes innovative in-silico optimization as well as alternative state-of-the art methods to ensure the success of the project. The targeted application of our offer is the structural biology field required by the pharma and biotech companies to develop and bring to the market any new drug.

With its partners, SYNTHELIS has developed new methods to accelerate the timeline to bring a protein from the gene sequence to the determination of its 3D structure. The cell-free system is at the heart of this process as the technology allows quickly producing, efficiently labeling and purifying a protein of interest. The openness of the system enables also to easily introduce some additives which accelerate for example the nucleation and optimize the phasing during the crystallization and diffraction phase.


OTHER INFORMATIONStructural biology combines biochemistry, molecular biology, and biochemistry, to analyze the molecular structure of macromolecules, such as nucleic acids and proteins, to reveal functional aspects of individual macromolecules that influence biological interactions. What makes Structural Biology particularly attractive is that all projects are directly connected to human diseases. When more than 50% of the therapeutic targets are membrane proteins, less than 1% has been structurally described. This illustrates the tremendous need in innovative methods to accelerate the structural determination of this class of proteins.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


SYNTHELIS is looking for partners bringing any additional value to accelerate or de-risk our process going from the gene sequence to the protein structure determination. We are also strongly interested by any partner with a project or a grant application in structural biology.


V E I N S O U N D

CONTACT CHARREL Thomas Position: CTO Phone: +33 (0)6 75 32 22 38Email: [email protected]

TECHNOLOGY OFFER

INNOVATIVE THERAPEUTIC PLATFORM DEVELOPMENT FOR FULLY EXTRACORPOREAL VARICOSE VEIN TREATMENT

Business model: Product developer - Other healthStrategic area of application: Medical technologiesApplication fields: Cardiovascular diseases, Dermocosmetics



20 to 25% of the industrialized countries’ population is affected by vein diseases – 730 million individuals – for about 2% of health care expenditure - € 10 billion per year.

All current available varicose vein treatments are invasive or need strong chemical agent to obliterate veins. Vascular doctors need a solution to treat patients in their office with less risk and at the early stage of the pathology. VeinSound engineers and commercializes revolutionary system solutions for delivering the only extracorporeal and truly non-invasive treatment of varicose veins and the venous system.

INNOVATIVE ASSETSVeinSound is offering a unique non invasive varicose vein treatment platform, leveraging its expertise in High Intensity Focused Ultrasound which technology has been developed in partnership with and patented by the INSERM - French Institute of Health and Medical Research - and INSERM Transfert has granted the Exclusive Perpetual and Transferable rights to VeinSound in the «Vascular Therapy» Field of Use.


VeinSound’s treatment solutions will address first the vascular doctor and specialist population and will empower them to deliver such services at their medical practices.


VeinSound is interested in partnership and advisors in Quality System and strategic regulatory orientation for EU and USA market deployment.


OTHER INFORMATIONThe worldwide varicose vein treatment market is estimated at € 10 billion annually with the lion-share distribution in Europe and the United States of America.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


B A R I A T R I C E A T I N G B E H A V I O R

CONTACT DOUGKAS Anestis Position: Research Scientist in Nutrition, Health and Eating Behaviour Phone: +33 (0)4 72 18 54 61Email: [email protected]

TECHNOLOGY OFFER

OBSERVATIONAL AND INTERVENTIONAL EXPLORATION OF THE EVOLUTION EATING BEHAVIOR IN PATIENTS WHO UNDERWENT BARIATRIC SURGERY (WEIGHT LOSS)

Stage of the project: Other (Consortium was build and PhD recruitment completed)Strategic area of application: Human MedicineApplication fields: Nutrition/Food

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESThe prevalence of obesity has reached epidemic proportions with currently 16% of the French population suffering from obesity. Bariatric surgery (gastric bypass (RYGB) or sleeve gastrectomy (VSG)) is currently the most effective treatment of sustained weight reduction not only by reducing food intake but changing food perception/preferences and eating behavior. Such a change in food preferences is the avoidance of protein enriched meals (meat dairy) leading to low protein intake (0.5 g/kg/day, while it is recommended 1.5 g/kg/day), which might be responsible for an excessive lean body mass loss, limiting weight loss or favouring the recurrence of obesity in the long term. Thus, there is a need for longitudinal studies assessing food reward, taste, olfaction and eating behavior in the same subject pre- and post-surgery and in a real context ecological environment.Project objective : To examine the impact of bariatric surgery on taste, smell, food/protein selection and food intake in a cohort of patients undergoing RYGB and VSG surgery.Overall objective : To identify nutrition tools and build successful meal interventions to encourage the adoption of adequate protein intake and healthy eating habits following the bariatric surgery.Research approach : It is proposed to obtain data from the cohort of 200 patients registered in Lyon’s hospital at the Research Centre in Human Nutrition Rhône-Alpes (CRNH-RA). The subjects are followed up at 3, 6, 12 and 24 months post-operatively.

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONThe majority of the studies examining the eating behavior followed by bariatric surgery performed observationally or in such highly unnatural designs, may thus be incompatible with the realization of accurate behavioral measurements. This study takes into account the importance of context and environment when study eating behaviors and particularly food choice.

Studies like this, incorporating more direct measures of target behaviors may help clarify whether alterations in food selection and changes in taste function accompany the decreased caloric intake and weight loss seen after RYGB.

This project will allow us understand to what extent and in what way, bariatric surgery impacts food preferences and describe the mechanisms of gustatory and olfactory alterations according to the type of bariatric surgery by comparing RYGB and VSG surgery in a longitudinal cohort.

Part of the scientific innovation is to validate the relevance of the Food Leeds Preference Questionnaire as a tool to assess food reward (liking/wanting) to French population and adapt it to bariatric surgery for assessment of the dietary preferences after bariatric surgery.

In the longer term it is expected to provide concrete nutrition tools and interventions for the development of innovative food products to counteract the difficulties of patients achieving successful weight loss and adequate protein intake and recommendations.

BLUESKY MEETING SESSION 2 : IDÉES DE PROJETS R&D OUVERTS AUX PARTENARIATS

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTED

By elucidating the mechanisms by which obesity surgery reduces consumption of high calorie foods and alters taste responses, new surgical and non-surgical therapies could be developed that mimic these processes and so promote safe and effective weight loss. It may even be possible to predict which patients would do well with a specific type of obesity surgery and thus provide guidelines regarding the type of surgery that could be more successful on the preoperative taste of the patient.



It is in the context of the association between two research centers: CRNH-RA (specialized in metabolic research nutrition) and the Institut Paul Bocuse Research Centre (equipped with the experimental restaurant). This project would benefit by a private funding entity to support the technical innovation on intervention and food development phase. Potentially we could also look for partners in order to develop a screening tool to detect troubles or for post chir follow-up?

FINANCIAL INSTRUMENT CONSIDEREDCIFRE for the PhD student has already secured and further additional funding for the various stages of the project will be obtained by AFERO foundation and other collaborative industrial-academic funding calls.

PLANNED SCHEDULEThe outline of the project, showing the timetable and the different phases:1. Familiarization with the scientific literature (1-2 months)2. Pilot phase (months 3-9)Ethical form file preparation / submissionLeeds Preference Questionnaire for Bariatric and French Population3. Observational phase (month 10-34)Ethical form file preparation / submissionAssessing olfactory and taste sensitivities for different types of bariatric surgeryEvaluate food preferences using the FLPQ in the cohort followed pre-operatively and at 3, 6, 12 and 24 months postoperatively4. Experimental phase (Experimental Living Lab) (month 10-34)Patient’s acute test meal within the longitudinal observational study at IPB (pre-operatively and at 6, 12 and 24 months postoperatively5. Valuing the results (months 34-36) to professionals and the general public (months 34-36)6. Intervention phase and novel food product development for the provision of concrete solutions to the patients (months 37- 60).

PI STATUSConsortium agreement will be signed between partners and will define all IP aspects between academic and industrial partners for all forecasting valorization.

Validation of the specific questionnaire will assist the care teams to have a tool allowing them to spontaneously address possible dietary difficulties during the post bariatric recovery and they will be able to propose specific recommendations to each patient on the choices of foods to favor in order to keep healthy eating.

Based on the scientific results, we will be able to formulate culinary recommendations in terms of variations in preferences for protein sources, sugars and lipid products between groups of different bariatric surgery for the patients, their family and the professionals of the restoration.

Last but not least, the technical innovations will provide guidance for industry for the development of foods that modify dietary habits and provide an alternative to protein shakes. Development of well tolerated and perceived new products with high nutritional values (mutlivitamins and trace elements), high quality protein content and low glycemic index could help the 50 000 French bariatric subjects/year and used for mass consumption in an attempt to replace the growing and profitable market of vitamins and dietary supplements.

etoN s...........................................................

...........................................................

...........................................................

...........................................................

..........................................................

...........................................................

...........................................................

..........................................................

...........................................................

...........................................................

...........................................................


B I O A C T I V E C O A T I N G S

PROJECT LEADER PICART Catherine Position: University Lecturer & ResearcherPhone: +33 (0)7 87 40 04 32Email: [email protected]

TECHNOLOGY OFFER

BIOACTIVE COATINGS IN MULTIPLE WELL CELL CULTURE PLATES

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESUsing the layer-by-layer assembly technique, the Picart team has developed innovative biomimetic films made of biopolymers (polypeptides and polysaccharides) that possess a controlled stiffness and present proteins/peptides to cells in a so-called matrix-bound manner, ie «at their ventral» side. This presentation mode lead to an amplified biochemical signalling transmitted to cells, at the receptor level, and trigger a faster and more efficient cell differentiation. These biomimetic films enables us to reveal so far hidden biological phenomena, which would not have been possible in «conventional» culture conditions. Currently, the team is working on two major applications of these bioactive coatings in bone formation and cancer therapeutics. The objectives of the project are i) the optimisation and automation of the technology, ii) the development of an efficient organoid model and iii) the transfer of our technology to business. The outcome of this project will be technical and commercial, since we will define the valorization model, either with a transfer of license or to the creation of a potential start-up.

Stage of the project: Proof of concept doneStrategic area of application: In vitro DiagnosticApplication fields: Metabolic diseases

ideal solution for stem cell culture and differentiation by adjusting the stiffness and matrix-bound growth factors, in order to form organoids in vitro. It can also be applied for cell-based assays and screening of drugs for improved therapeutic treatments. ii) The compatibility with high throughput screening (HTS) and high content screening (HCS) equipments as well as optical imaging (fluorescence, luminescence, absorbance) using commercially available microscopes and microplate readers. As a thin surface coating (few nanometers to few micrometers), the biomimetic films are transparent in the UV/ visible range, which enables cell characterization directly (in situ) in the wells with traditional screening equipment. There is no need to transfer the cells in other wells. iii) The automation of layer-by-layer film deposition in multiwell plates. This innovative process paves the way for the industrial production of the biomimetic films and more widely for other researchers working on LbL field for different types of applications in materials science and chemistry, such as energy devices, optical coatings, catalysis...

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDThe major already commercial products are extracellular matrix coated plates. According to Horvath P and Caragher (in Nature Reviews in Drug discovery, 17-751, 2016): «Cell culture assay systems must be revisited. Current efforts should be directed towards the development of new models, new assay formats andinnovative screening technologies that better recapitulate in vivo physiology to advance preclinical disease modelling and drug screening across challenging disease areas.» Innovative physiological cell culture substrate. To our knowledge, our biomimetic films will be the first product on the market that provide both physiological stiffness, bioactivity and is compatible with high throughput content screening. In addition, the good affinity of the biomimetic films to various proteins will give flexibility to the end-users for them to modify surfaces with their desired proteins. Cell-based assay product. The development of medications with higher efficiency and lower toxicity is always a challenge in pharmaceutical industry. We foresee applications of our biomimetic films to treat bone disease (such as osteoporosis) or to develop new cancer therapeutics. More broadly, since we can load several proteins from the bone morphogenetic family, chemokines as well as other proteins and peptides, we foresee other potential applications that are not fully defined at this stage.


SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONBased on the automated biomimetic film deposition in multiwell plates, it is now possible to provide researchers with reproducible biomimetic films for cell biology studies, with a stiffness and biochemical control of the films by trapping proteins or peptides. The innovative characteristics of our technology are: i) Unique physico-chemical properties. The combination of tuneable substrate stiffness with matrix-bound bioactive proteins. As far as we know, our technology is the only one that can perfectly combine the two factors to mimic an in vivo environment. It is an


PI STATUS- Process for preparing a surface coated by crosslinked polyelectrolyte multilayer films as a biomimetic reservoir for proteins; (Univ Montpellier 2 and CNRS). Crouzier T and Picart C. filed in Europe and US; delivered in 2014 and 2016.-European Patent filed in December 2016 (INPG and CNRS), Dalonneau F, Lie J and C. Picart : «Robotic method for coating a multiwell plate by a polyelectrolyte multilayer film» under examination.

KIND OF PARTNERSHIP INTENDED

- technical partnership to further develop image acquisition and analysis at high throughpat with :- pharmaceutical/ Biotech companies that produce bioactive proteins (growth factors, chemokines) or peptides under GMP conditions in order to buy them in batch with high purity- academic labs that want to work on more physiological surfaces for their cell (or stem cell) studies- manufacturer of cell culture plate- manufacturer of automated liquid handling machine to implement our concept to their machine- human resources: we are looking for a highly motivated post-doctoral researcher to work on this project in view of the possible creation of a start-up company.

FINANCIAL INSTRUMENT CONSIDEREDCurrently, the project is supported by an ERC Proof of Concept Grant (BioactiveCoating) to CPicart (May 2016-September 2017) Il will pass the «Investment Committee» from the SATT Linskium of Grenoble on 21/09/17 and will officially start in January 2018.

PLANNED SCHEDULEWe have organized our project in four workpackes :1. Optimization of the technology for high throughput analysis2. Bioengineering of an in vitro mini-bone model3. Diffusion of the technology outside of the lab (in collaboration with academia and industrial partners)4. Market studies5. Development plan.

ILLUSTRATIONLegend: BioactiveCoatings

Copyright: Catherine Picart

etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


Using a bioextrusion technology, our team is working at printing highly organized tissues, with a particular focus on skin. The conventional strategies in the field of tissue engineering led to the development of models having a poor stability, a predetermined geometry and being time consuming. To overcome these limitations, 3D printing was proposed to demonstrate the potential of tissue bioprinting.

The project targets two distinct fields: 1/ Bioprinting of substitutes for therapeutic area in regenerative medicine (such as treatment of severe burns, wounds with loss of substance, reconstructions after traumatism or surgery ...) and transplants. 2/ Bioprinting of functional tissues for R&D and preclinical testing purposes (ingredient screening, drug discovery, safety and efficacy testing of products, biocompatibility testing of medical devices...), and as new predictive tools for therapies evaluation, or for disease modelling.

B I O P R I N T I N K

CONTACT DURAND Caroline Position: Project leaderPhone: +33 (0)6 67 18 46 01Email: [email protected]

TECHNOLOGY OFFER

BIOPRINTINK : 3D BIOPRINTING OF FUNCTIONAL LIVING TISSUES FOR R&D AND MEDICAL USE

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVES

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONDespite recent progress in bioprinting, scaffold-free skin bioprinted model engineered with human cutaneous cells is still not available. The bioprinting innovation presented here is capable to produce dermis/epidermis systems in an effective way and with a cellular structuration of the mature tissue highly similar to the in vivo skin organisation. We have developed a unique bio-ink together with strictly optimized printing conditions and 3D printer functions.

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDOur technology based on microextrusion bioprinting allows the production of biological human tissues. The markets targeted are the personalized regenerative medicine therapies (burns, recontsruction…) and Pharmaceutical laboratories needing predictive tissues to test the efficacy of drugs.Regenerative medicine : The bioextrusion 3D printing we choose, perfectly matches the clinical needs with tissues of complex shape and especially of compatible sizes with physiology. The improved reproducibility and quality of the manufacturing process, and the GMP grade of the bio-ink, make these engineered tissues elligible to became Advanced Therapy Medicinal products.We have already produced a living bioprinted skin, a world first. A project supported by ANR/DGA has been launched, for the tissues bioprinting on sever burned soldiers.R&D and Preclinical testings : The high level of reproducibility and quality of bioprinted models, necessary for industry and regulatory purposes, allow optimization of researcher’s results and consistency of statistical analysis on living in vitro tissuesMoreover, the highly-relevant and predictive microphysiological platform, mimicking the form, function and complexity of native tissue in vivo, allows development of alternative methods to replace animal testings.

Stage of the project: Incubation phaseStrategic area of application: Human MedicineApplication fields: Regenerative medicine and R&D testings


The process was divided in three steps: the printing process itself, the consolidation, and the maturation during which printed cells were free to interact together. This process and bio-ink formulation were the keys to the successful printing of complex 3D objects containing living cells and having size in the centimetre range.3D bioprinting approach offers significant advantages compared to contemporary skin tissue methods: - Spacial control, Precisely positioning of biological materials, biochemicals and living tissue ;- Complexity, Integration of multiple cells types in sufficient resolution to recapitulate biological function ;- Shaping, Spatial control of x, y and z axes, to create functional and customized tissues in wide range of sizes, thickness and shapes ; - Reproducibility, Automation of the printing process allowing production in a highly reproducible manner ;- Speed, High-throughput printing process using specific bioprinter.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


We are looking for new partnerships with experts in the fields of biomaterials science, cell biology and medicine :- to improve our first models, as inducing vascularisation or integrating other type of cells, - to develop new models, especially epithelia.

PI STATUSPCT Patent has been applied for the bioink and manufacturing process of engineering tissues by bioprinting process (Global Patent 2628).

FINANCIAL INSTRUMENT CONSIDEREDOwn founds.

PLANNED SCHEDULEThe end of the year is dedicated to the realisation of new proofs of concept. The legal structure should be created in Q1 2018.

ILLUSTRATIONLegend: Bioprinter/Ear Bioprinted/Skin Bioprinted

Copyright: Labskin Creations


F E A L I N X

CONTACT VIRIEUX Bruno Position: Deputy CEOPhone: +33 (0)6 40 31 36 34Email: [email protected]

TECHNOLOGY OFFER

ULTIMATE IT SOLUTION FOR “IN SILICO” MEDICINE

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESSWOMED is an IT framework which helps organizations (such as academic lab & big pharma) to find, develop and commercialize the new generation of biomarkers & drugs, to ultimately switch from curative medicine to predictive care.We aim to be the ultimate IT Solution for «In Silico» Medicine. From 2011, we have managed or participated to collaborative projects (ANR) in France and we co-lead with the GIN based in Bordeaux U5293 a LabCom called Ginesis Lab (ANR-LCV2-0006-01).

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONComplete IT solution to:- manage research from raw data to biomarkers, simulation algorithms or predictive models.- valorize them thru an innovative cloud platform.


Stage of the project: Execution Strategic area of application: Human MedicineApplication fields: Cardiovascular diseases, Neurology, Oncology


Our targeted market is the new generation of biomarkers’ market (such as defined by FDA in the BEST program). The global market is estimated to 41B$ in 2016 (D&C Consultants) and should reach 100B$ by 2021 according to BBC Research.Economic impact: new financing model for academic labsScientific impact: direct link between latest researches and medical practices.Technical impact: total traceability of data from medical study to medical systems.

PI STATUSMost of breakthroughs are public as we published papers in scientific review.Nevertheless, we own two different kind of assets:- Programs & Algorithms (especially Machine Learning algorithms)- Know-how to deploy & dedicated team to do it (defined as Complex Problem Solving ‘COPS’ Team).


We look for:- other companies & academic teams which are ready to work on ambitious collaborative projects such as ANR, PSPC... programs.- lab which wants to valorize their biomarkers, algorithms and predictive models using an innovative got to market.Our areas of interest are particularly oncology, multiple sclerosis, diabetes & cardiovascular diseases.

FINANCIAL INSTRUMENT CONSIDEREDFunds raising.Public grant.

PLANNED SCHEDULEQ4’17: US incorporationQ2’18: First biomarkers available on the storeQ3’18: US office opening


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


H O & M ECONTACT GADUEL Charly Position: Manager of the health domainPhone: +33 (0)7 81 16 44 62Email: [email protected]

TECHNOLOGY OFFER

HOSPITAL & ME

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESAccording to the current rules and based on the recent researches about chronic diseases’ evolution, an application helping medical staff to manage the growing number of patients and giving them a mean to watch all their patients in the same time, focusing on the highest priorities, is a real need and a way to optimise the comfort of patients. Indeed, the application’s engine is based an Artificial Intelligence permitting to personalise the interactions with the patient -as a doctor could do during a consultation- whatever his location (at home, or wherever), and generates warnings, that the medical team can monitor. Thus, patients can go back to home earlier in the medical protocol, with a mobile application watching them: the aim is to rationalise the patients’ hospitalisations by reducing the time spent in the hospital (reducing in the same time the risk of over infection and increasing their mood going back to a comfortable place > home), and in the same time optimise the medical time used to treat patients by focusing on patients requiring more attention. Another midterm objective will be to anticipate risks, avoid warnings and so prevent troubles, by bounding the machine learning of the Artificial Intelligence with the collect of historical data and external ones with Big Data. Those components make us different from our main concurrent. Concerning use of the application, all domains can be envisaged: from nutrition to rheumatology, or cardiology, occupational health care, veterinary medicine, etc.The last objective -not least- is to open the application to office-based practice. Sharing information between doctors inside hospital is the goal of Groupements Homogènes de Territoires; but we can go further, putting patient in the middle of the situation and share information between doctors from hospitals and office-based practitioners.

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDThe goals and impacts are multiple: medical treatment’s optimisation, cost rationalisation, digital’s boom for the medical domain, ecological gain (green IT), The artificial intelligence will permit to raise warnings earlier, and the predictive analyse will permit to anticipate them and even avoid them. Knowing the number of patient is going to blow up much faster the medical team, this application will permit to the medical staff to only focus on patients requiring attention, rationalising their time. In addition, if the number of patients in the hospital is lower bound, then the structure will have less costs for the same of patients, because they are at home (night spending are saved for the hospital), the risk of over infection is limited, and their mood is better (placebo effect). The artificial intelligence will also permit to push the more appropriate content to the patient based on the experience (historic of data). With Big Data, the application will be able to learn from the historic of each patient, and customize the relationship with him.

Stage of the project: Other (Developments of the application are in progress (ready to show))Strategic area of application: Medical TechnologiesApplication fields: Other (Cross domains, this mobile application can be used in every context: each specialty has its own protocols based on quizzes)

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONThe innovation is more technical: it permits to improve the medical approach and keep the adhesion of the patient to the application all along his protocol, by giving in the same way all keys to doctors to set easily their protocols. Having a smart contextualisation of interactions between patients and the application, requires combination of Artificial Intelligence and Big Data. The lojelis’s expertise on the new technologies and digital solutions is used here to merge competencies of both technologies to simulate the exchange with the doctor. Keeping adhesion for the application is a hard stuff, that’s why lojelis invests on Gamification with specialists. The goal is to make patients want to answer their quizzes, consult tips and follow personal indicators (like activity trackers, mood or pain follow-up, or any indicator that the doctor judged pertinent to be consulted by the patient). That’s why the mobile application contains challenges and rewards (ex: personal objectives can be challenged with community ones or personal records; each loose of weight can increase an account with virtual money, that can be transformed into real donations to medical associations; etc.) that would encourage patient to use the application. Ergonomics and ease of use are the pillars of the back office, dedicated to doctors. It permits to create tips, patients, etc., assign quizzes to patients easily. The part requiring more reflexion is the quiz: that’s why the interface has been extremely simplify to permit to a non-IT person to create it, just clicking and selecting options.



etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

FINANCIAL INSTRUMENT CONSIDEREDAll the invests made for the moment are based on the own lojelis funds.

PLANNED SCHEDULEBy the end of 2017, the first version would be available with basics functionalities. Then will arrive much more complex features, but in order not to reveal confidential items, we will not say more. The edition plan is for long term.


Two kind of partnership can be intended. First, the application needs to be tested, validated and improved by doctors. So, we already worked on this medical approach to give the application the required credit to be reliable and relevant to prospects. We are working with different professors in various specialities. Secondly, the application’s development costs and we need financial partnership to trust and invest in the concept, to continue and upgrade the product.

PI STATUSThe name and logo of the application have been chosen and protection’s process by the INPI is in progress.

Finally, the engagement for the green IT will permit to save resources by avoiding useless journey to the hospital. When the patient is healthy, there’s no need for him to go back to see the doctor: so we can rationalise control’s visits and save relative fuel and time. The application will permit to put up with the massive coming of new patients.


M E C A C H I P S

CONTACT MIGDAL Camille Position: ResearcherPhone: +33 (0)4 38 78 23 55/+ 33 (0)4 38 78 47 95Email: [email protected]

TECHNOLOGY OFFER

TOWARD MORE PHYSIOLOGICAL IN VITRO CELL CULTURE

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESUp to now, cell culture and cell tests performed in research laboratories, pharmaceutical industries or screening platforms are mostly operated on plastic (or glass) dishes, which rigidities are about gigapascal (GPa). However, our organs are «soft», with rigidities span between few Pa and few tens of kPa, thus more than a billion times softer than usual in vitro culture conditions. Then standard culture dishes do not faithfully replicate the mechanical environment of cells in tissues, thus lacking of in vivo relevance. This shortcoming isa true limitation, as many studies have proved that the mechanical properties of the micro-environment deeply impacts almost every aspect of cell behavior (e.g. adhesion, spreading, migration, proliferation, differentiation) for a vast number of cell types including neurons, skeletal myoblasts/smooth muscle cells/cardiomyocytes, osteoblasts, chondrocytes, hepatocytes, fibroblasts, endothelial and epithelial cells and stem cells. The Mecachips technology fills this gap, and designs a completely new generation of cellular culture plates that combines an unprecedented micron scale control of the plate mechanical properties with an independent control of the surface chemistry.

Stage of the project: Manufacturing (small scale) Strategic area of application: Medical TechnologiesApplication fields: Other (Biomaterials/Cell biology consumables)

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONMecachips offers new, soft, biomechanical substrates for in vitro cell culture that mimic the in vivo mechanical properties of almost all our tissues (from 0.5 to 200 kPa) including mechanical heterogeneities as micron to millimetre-scaled rigidity gradients. More precisely, our innovative and patented technology allows the elaboration of a soft and flat layer made of polyacrylamide hydrogel that exhibits uniform or patterned elastic properties, and supports long time cell cultures

without degradation nor modification of its mechanical properties. Unique is the ability of Mecachips culture plates to mimic physiological mechanical heterogeneities of the extracellular matrix on a single plate. For the first time, Mecachips technology provides soft culture dishes that are pre-coated with proteins of the extracellular matrix, thus assuming the chemo-mechanical robustness of the culture environment. Then, Mecachips culture plates are very easy to handle and ready-to-use, similar to plastic or glass culture plates. Standard culture dishes size and format are being developed (i.e. from BP35 dishes to 384 wells microplates).


Mecachips culture plates overcome one of the major limitations of in vitro cell culture by enhancing the mechanical physiological relevance of the in vitro test. For the first time, a reproducible modeling of human-scaled, mechanical features of real cell environment is available in a culture plate. Hence, Mecachips plates may be considered as pioneer «in-vivo like» culture plates. Accordingly, we envision that these new culture plates will drastically improve the relevance of in vitro assays in the context of the transfer toward clinical and industrial models, thus greatly reducing the amount of necessary vertebrate euthanasia. In terms of social benefit, Mecachips may enable novel and more efficient protocols of personalized medicine, which clearly could impact tens of millions of people: for instance, when used with inducedpluripotent stem cells, it will be able to address regenerative medicine issues of high social impact such as cardiac, neural, skin, soft connective tissues or bone repair. Finally, compared to existing products, Mecachips culture plates are the sole ready-to-use, easy to analyze soft culture plates on the market of cell biology consumables.


PI STATUSPatent: WO2013079231


We look for CRO partnership to drive a drug screening assay on Mecachips up to preclinical stage.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

FINANCIAL INSTRUMENT CONSIDERED> Academic fundings: 305 k€> Exploitation and transfer fundings (CEA): 480k€> Linksium: 170 k€

PLANNED SCHEDULECurrently, the Mecachips project is in maturation with SATT Linksium (Grenoble) and we plan to create our start-up in 2018.

ILLUSTRATIONCopyright: Mecachips®


M I M E S I S

CONTACT GUYON-GELLIN Nicolas Position: VP Corporate Development & StrategyPhone: +33 (0)6 08 16 10 67Email: [email protected]

TECHNOLOGY OFFER

A NOVEL SYSTEMS BIOLOGY APPROACH TO DEVELOP PRECLINICAL ASSETS FROM INNOVATIVE DRUG DISCOVERYSTARTING POINTS INSPIRED BY VIRUSES

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESMIMESIS project results from the scale up of ENYO’s innovative drug discovery engine inspired from virus strategy to modulate cell functions. ENYO Pharma has designed a proprietary library of 10’000 small molecules that modulate host cell biology. This library of developable chemical templates are currently screened in phenotypic assays against 4 viruses (Flu, RSV, Zika and HRV), a mycobacterium (TB) and as inducers of Immunogenic Cell Death in tumors. With €3.6 millions spending over 24 months, most promising chemistries will be the starting point for numerous hit to lead optimization programs funded within the EU grant. Those optimization efforts will generate Intellectual property.MIMESIS project intends to:> Generate a small molecule library to identify modulators of a hundred human pathways known to be targeted by viruses. As human intracellular cell targets implied in several pathways, the molecules can also be developed in a wide set of pathologies.> From the output of cell based screens, prioritise targets and the molecule starting points for internal drug development of 5 hits.Discovering therapeutic starting points that modulate hundreds of novel human targets will have game-changing impact in the pharmaceutical industry and foster drug and clinical development opportunities for the benefit of the community.

Stage of the project: Proof of concept doneStrategic area of application: Human MedicineApplication fields: Other (Infectious diseases and oncology)

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONENYO Pharma has a unique approach through its drug discovery engine to identify patentable chemistries directed at new human disease targets. It is based on the mimetism of virus strategy to modulate host intracellular pathways. The efforts of ENYO’s founders over 10 years allowed the creation of a sophisticated database containing all known and curated Virus Protein-Human Protein Interactions. ENYO Pharma was founded on the conviction that the detailed understanding of a physical interaction between virus and host proteins would allow the design of novel, small therapeutics molecule able to modulate diverse cellular functions - in the same way viruses do. By looking at host targets, the discovered targets can also be implicated in non-infectious diseases and can be the starting point of first-in-class drug development. The company is currently developing treatments against liver diseases (chronic HBV and NASH) and plans to conduct its molecules to Phase II clinical trials by 2018.

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDIn many therapeutic areas, significant unmet clinical need remains. In the last decade, the pharmaceutical sector has been facing fundamental dilemmas with rising development costs, patent expiries, high attrition rates…In addition to the above, the rate of innovation in pharmaceutical development is low. This results from a focus on a restricted number of drug target classes considered more tractable and emphasis on developing “me-too” drugs that are clinically equivalent therapeutics to replace pioneering drugs.

ENYO approach aims at developing first-in-class drugs and brings a new approach to answer several issues by:> Discovering new cellular targets considered until now as untractable while many other companies focus on a restricted number of traditional cellular targets. > Using phenotypic screens that are more successful in identifying first-in-class new molecular entities than target-based approaches. > Developing new arsenal approach in infectious diseases (by targeting the host instead of the pathogen) and in oncology (by finding new targets and drugs).It could thus allow to develop drug in infectious diseases where the unmet need remains high given a lack of innovation but also in many other indications.



etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

PI STATUSThe project is currently under progress and IP is planned for 2018.

MIMESIS project will generate many and various Hits. ENYO Pharma will further optimize some of its best chemical series either internally or in collaboration with other pharmaceutical companies up to clinical proof of concept. The company could indeed consider different kind of collaborations, like transfer of ownership rights or form a co-development partnership. The company will mainly focus on molecules targeting respiratory viruses and oncology, but even in these areas, the number of found hits can be too important for ENYO to develop all of them.


FINANCIAL INSTRUMENT CONSIDEREDENYO Pharma’s MIMESIS project applied for the June 2016 cut-off Horizon 2020 SME Instrument program under the topic “Dedicated support to biotechnology SMEs closing the gap from lab to market”. Horizon 2020 is a EU framework program dedicated to innovation and research managed by the European Commission. It aims to support high growth and highly innovative SMEs with global ambitions. The company will receive 2.5 M€ from EU corresponding to the financing of 70% of the total project budget.

PLANNED SCHEDULEProject MIMESIS was launched in November 2016 after the agreement of the proposal by the European Union (Horizon 2020 SME Instrument Phase 2 grant). Within the next two years, we will be able to complete the project and submit patent applications of new and original small molecules. Here are the main milestones of the project:2017:- MIMESIS Molecule library available- Screenings for Hits- Hits Validation & Prioritization.

2018:- Hit to lead Optimization- Business development and Market approach- Patent application of the small molecules.


P A C L I O

CONTACT CHAVEROUX Cédric Position: Chargé de Recherche CNRS, Groupe S. ManiéPhone: +33 (0)4 69 16 66 22Email: [email protected]

TECHNOLOGY OFFER

PAIRED CELL LINES IN ONCOLOGY

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESOur laboratory studies the metabolic mechanisms allowing adaption of tumor cells facing microenvironmental stresses and therapies. We are developing a cellular engineering project that aims at modeling in vitro pulmonary cell transformation and lung tumor microenvironment by using fresh human tissues. We have already optimized the separation process of healthy cells from distal tissue of lung cancer biopsies. By immortalizing these cells, we will generate the first paired-cell models in oncology associating non-cancerous epithelial cells and tumor cells from the same patient sample. This system will also allow the isolation of epithelial cells from patients suffering of chronic obstructive pulmonary disease (COPD) or smoking.

Stage of the project: Basic ResearchStrategic area of application: Human MedicineApplication fields: Oncology (Lung diseases)

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONDeveloping paired-cellular models will offer several advantages for preclinical studies on lung pathologies:- Creation of a large panel of non-tumoral cell lines for anticipating potential side effects of treatments (most of cell lines available are tumor cells). Based on the patients’ etiology, we will provide non-cancerous cells from healthy patients, smokers or people with COPD.- Limitation of the genetic background variation on drugs response as the paired models derivate from the same patients.- Possibility to generate collections of paired-cell models based on mutations present in the tumor. This allows the comparative studies of mutations outcome involved in therapies resistance with the healthy counterparts.

- Possibility to genetically modify normal cells to study oncogene-related transformation process.- Possibility to co-culture the cells to model tumor microenvironment and study cells communication.

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDCell lines available on the market are almost exclusively derivates from tumors. The lack of non-cancerous cellular models is detrimental for basic research in oncology and drug testing. We believe that non-cancerous cell lines for preclinical studies offer a novel and relevant tool for first evaluation of therapies. This cellular system represents an alternative model for the first-line evaluation of toxic effects of a candidate drug on paired non-tumoral and tumoral cells. It also permits to anticipate its effects on epithelial cells from patients with pneumopathologies. Finally, estimation of drug toxicity on these paired-models could help in the decision to proceed to animal testing, saving time, money and being moreethical in the drug development process.


PI STATUSUnder review

Private/Public partners for cell culture expertise (ex: 3D culture) for improving the first paired model in lung cancer. Possibility to use the same approach for other organs. Market orientation.


FINANCIAL INSTRUMENT CONSIDEREDPublic-Private partnership including: ANR, call from Region Auvergne-Rhone-Alpes, CLARA, ERC and INCa.


etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

PLANNED SCHEDULEUp to now, we have: (i) optimized the process for separating and isolating non-tumoral epithelial cells and the cancerous cells from the same biopsy (ii) defined the optimal cell culture conditions for maintaining both primary cell models. During the next trimester, we plan to immortalize our first cell lines and demonstrate our capacity to generate the paired-model. Then we will evaluate the feasibility of this project between 2 to 4 years depending on the human and financial resources.


Q D D P

CONTACT MALLOL Roger Position: Scientific project coordinatorPhone: +34 977920200 (Ext. 129)Email: [email protected]

TECHNOLOGY OFFER

IN VITRO DIAGNOSTIC PLATFORM FOR NON-INVASIVE BIOMARKER QUANTIFICATION

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVESThe field of clinical diagnosis is in constant search for new methods to detect key biomolecules that constitute relevant biomarkers for a wide range of diseases. One example is cystic fibrosis (CF), the most common fatal genetic disease. Sweat testing continues to be the gold standard for CF diagnosis although, even performed properly, it is not always conclusive. Indeed, although the results of this test are valid any time after a baby is 24 hours old, collecting a large enough sweat sample from a baby younger than 3 or 4 weeks old may be difficult. To overcome these limitations and others, the field of clinical diagnostics requires that the tests show high standards of specificity and sensitivity, as well as being rapid, easy to use and may be performed using standard instrumentation. Further, clinical tests are preferred that are user-friendly and suitable to apply at the point-of-care, for which they need to be scaled down to small devices. Finally, multi-analyte tests, a type of multiplexing tests in which multiple analytes are measured and each analyte measured corresponds to one distinct diagnostic answer, are also of paramount importance. Here, we propose to 1) validate clinically a multi-analyte diagnostic platform based on quantum dots, 2) to scale this technology to also determine other biomarkers and 3) analyze business opportunities to transfer this technology into the clinical market.

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATIONThe Institute of Chemical Research of Catalonia (ICIQ) is a foundation created in 2000 by the Government of Catalonia that started its research activities in 2004. ICIQ is nowadays an internationally recognized leading institution in the field of chemistry. The research group of Professor Palomares, ICREA Professor at ICIQ, has developed and protected a new platform for the quantitative measure of hydrolytic enzymes (http://www.iciq.org/wp-content/uploads/2013/11/EP-2013-011.pdf). This new platform consists of two silica nanospheres arranged concentrically and embedding a core of quantum dots nanocrystals with different luminescence emission maxima. At the present, there exists a proof-of-concept, published results, and some patent rights granted in Europe and pending in the United States. We have tested this in vitro diagnostic platform for the diagnosis of cystic fibrosis and currently we are evaluating other clinical applications.

Stage of the project: Proof of concept doneStrategic area of application: In Vitro DiagnosticApplication fields: Genetic/Rare diseases (Infectious diseases)

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDCurrently, the treatment of cystic fibrosis (CF) is expensive and optimal results are commonly associated to the implementation of dedicated centres, which is not always possible. The estimated cost, according to literature, is between $6,200-16,300 per patient (1996 values). Moreover, the cost increases with the age of the patient as the risk of infection by microorganisms such as Pseudomonas aeruginosa also increases. Studies on the economic impact of CF calculate that early diagnosis that lead to the delay of chronic Pseudomonas aeruginosa infection in CF patients by 1 year save more than 25,000$ per patient. An early diagnosis will also benefit to the integration of CF individuals in the society: children with CF may suffer from delays in their educational level if the diagnosis is carried out in late stages, as the lack of medication will affect their normal life. Latest studies on CF population show that the educational level in CF individuals is comparable to the general population when medication starts early.From the technical point of view, we envision a non-invasive, fast, accurate, and versatile diagnosis platform, applicable at point-of-care and with potentially lower number of false negative than currently implemented ELISA tests. Our technological platform has the ability to be applied in multiple indications in both developed and developing world clinical applications with no need for lab infrastructure or lab personnel. Thus, this innovative technology hold the potential to change dramatically the diagnostic paradigm by offering broad menus of tests in a variety of sample types that previously required multiple detection technologies.



etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

FINANCIAL INSTRUMENT CONSIDEREDICIQ, through funding obtained from “La Caixa” Foundation, has awarded us recently with a Product Incubator grant (1 year - 85K €) aimed at developing valorization and technology transfer activities to further develop our diagnostic platform. This grant will allow us to further develop this technology from the technical and clinical point of view as well as prepare the creation of a spin-off company. In this line, we will consider the proper financial instruments that will foster the initiation of the company’s activities, from public loans and grants to private investments and industrial partnerships.

PI STATUSWe hold a granted European patent covering the biomarker and the diagnosis method to protect the innovation. We filled said patent in June 2013 and, in 2014, we pursued patent prosecution at the PCT stage. These patent applications cover the platform for enzymatic activity detection and is not restricted to the case of cystic fibrosis. We further extended patent portfolio in 2015-2016 in Europe and USA, along with national phase entry.


We are open to collaboration in different directions. First, we will welcome collaborations to foster the clinical validation and expansion of our technology. Second, we also seek partners to conceptualize the final product to be developed as a diagnostic platform. Finally, we are looking to interact with potential investors who are willing to be involved in technology transfer processes in order to turn scientifically disruptive technologies into marketable products in the medical technology industry.

PLANNED SCHEDULEWe divide the product development process into three main phases: 1) technology transfer and valorization activities, 2) early-stage startup activities, and 3) commercialization through late stage start-up and/or larger industrial partners. The aim of this project is to cover the first phase of this road map, i.e., the technical optimization of the test, its first clinical utility study (in collaboration with clinicians from Hospital Parc Taulí) and a business plan analysis. In subsequent phases, we will participate in different clinical studies to generate more scientific evidences, as well as product attributes for different clinical applications and dissemination to the national and international clinical community. As a result, we will market the kit once we overcome the regulatory barriers. Notably, a collaboration with industrial partners will enable the industrial development and introduction of the kit into clinical practice through a more consolidated business infrastructure, market knowledge and an extensive commercial network.


S I N N O T E S T

CONTACT GIROD-ROUX Pierre-Marie Position: CEOPhone: +33 (0)6 74 28 51 66Email: [email protected]

TECHNOLOGY OFFER

PREDICTIVE MEDICINE FOR CHRONIC INFLAMMATORY DISEASE

SHORT PROJECT DESCRIPTION: CONTEXT AND OBJECTIVES

Biologics have considerably improved outcomes and prognosis of patients suffering from RA and AS but clinical practice shows that 35% of them do not respond and miss the important treatment window of opportunity, resulting in useless public spending, out-ofpocket payments, loose of chances and side effects. Recognizing this major problem, SINNOVIAL proposes an on-line SINNOTEST enable to determine a priorithe biotherapy best suited to the patient, according to its specific proteomic profile (SINNOVIAL identified patented biomarkers). Such test does not currently exist. Our technology: from a simple blood sample, SINNOTEST can predict the effectiveness of biologics before their prescription based on the analysis of specifics biomarkers of the patient. (Teaser video available: https://www.youtube.com/watch?v=VWFPG0zZpn4) Our mission: to improve the quality of life of patients suffering from these invalidating diseases by maximizing the chances of treatment success and to reduce useless medical spending for both healthcare systems and patients. Our aim: to provide physicians with a secure, validated, value-based priced, easy to use and effective predictive therapeutic guidance tool that enable them to optimize the selection of biotherapies. Transforming science into a value added offering, SINNOVIAL then engaged into strategic development actions (user-centred software, proprietary algorithm, quality management and (pre)clinical studies).

SCIENTIFIC, TECHNICAL OR COMMERCIAL ASSETS / INNOVATION

Understanding the urgent need for predicting a patient’s answer to biologics treatment in Rheumatology, SINNOVIAL chose to target RA and AS first because of their epidemiological and financial impact. SINNOVIAL disruptive and proprietary technology emerged from more than a decade of fundamental and clinical researches programs at GREPI (Groupe de Recherche et d’Étude du Processus Inflammatoire, EA 7408 University Grenoble Alpes, France; Baillet A et al. 2010; Trocme C et al. 2009; Baillet et al. 2010). From its long scientific expertise, SINNOVIAL has setup and masters all the procedures to generate a functional online predictive software from patient’s samples: o Pan-proteomic analysis of patient’s samples from a study cohort to rapidly discover and identify differential biomarkers in responder vs non-responder population;o Selection of the most relevant biomarkers allowing discriminating future responders from non-responders to specific biologic before its prescription; Assessment of biomarkers concentration in routine automated techniques (nephelometry, turbidimetry, etc.) by classical analytic laboratory; Generation of algorithm to predict response to the selected biologic and implementation into the online predictive SINNOTEST software to make the tool available to clinicians. SINNOVIAL designed a first generation of software called SINNOTEST, to implement and commercialize this powerful predictive tool in a form of a secure on-line software.

Stage of the project: Clinical phase IStrategic area of application: Human MedicineApplication fields: Autoimmune diseases

ECONOMIC SCIENTIFIC AND TECHNICAL IMPACTS EXPECTEDSINNOVIAL will bringing to 2.6 million newly diagnosed patients every year an innovative cost-effective predictive test enabling physicians to adopt a personalized approach of rheumatology treatment for patients suffering from rheumatoid arthritis (RA) or ankylosing spondylitis (AS), the main chronic inflammatory rheumatology diseases. Clinical practice shows that 35% of patients will not respond to biologics. Considering population ageing & an annual cost of these diseases ranging from €13k to €42k, the bill isskyrocketing, yet medical value of new treatments is not fully leveraged. By being able to select the best biologics for a patient based on their proteomic biomarkers, SINNOTEST will answer the rheumatologist’s request for improved clinical decision making, which currently combines «clinical signs, subtle medical acumen and luck» & aim at reaching an 90% response rate in patients, thus significantly increasing a patient’s chance of receiving quickly the most effective treatment.



PI STATUSA methodology patent was registered in 2013 by the innovation department of Grenoble Alpes University (Floralis) following freedom to operate studies. A full exclusive license was given to SINNOVIAL SAS in September 2015. Key coverage points include secret known-how regarding algorithm design and cut off assessment of identified biomarkers. Our patent attorney from Regimbeau, actively monitor the field to anticipate any potential threats.


A first online SINNOTEST software version can already be used by hospital clinicians under investigational device exemption rules ; TRL 7: «system prototype demonstration in operational environment».Our short-term project will include a clinical trial to validate the performance and optimized this predictive tool and achieve TRL 8/9 «system complete and qualified» (TRL8) and «actual system proven in operational environment» (TRL9).Partnership:- Pharmaceutical company- Diagnostic company

FINANCIAL INSTRUMENT CONSIDEREDSINNOVIAL is targeting the 2.6 million patients newly diagnosed with RA or AS every year and more globally the 40 million patients affected by the disease, with a 16% increase in prevalence between 1995 and 2007 and a 28% planned increase in prevalence for rheumatic conditions overall in the next 15 years. Considering a value-based cost of 300¤, this represents a potential market of 137 million¤ for all RA and AS incident patients in industrialized countries. Investors discussions ongoing.

PLANNED SCHEDULE

The project duration is 30 months and the work is organized in 5 work packages.Prerequisite steps will be carried out before the start of the project, so that clinical trial in France will be able to start at the very beginning of the program.These activities are financed directly by SINNOVIAL:- Development and Certification of Graphical User Interface- Ethics issues and regulatory authorizations (France Submission to CNIL (FR only); to CPP and ANSM)The main WP1 is dedicated to multi-centric trial of the SINNOTEST medical device realized in 5 major hospital centers. Clinical results will confirm SINNOTEST functionality, to obtain final commercial version (WP2).In parallel (WP3), SINNOVIAL will realized all necessary regulatory steps, CE marking and will organized patient data base storage using a secure data center.WP4 and WP5 are focused on worldwide market access analysis and exploitation of results, as well as on large dissemination and communication activities.

ILLUSTRATIONLegend: SINNOTEST PROCESS

Copyright: SINNOVIAL SAS

etoN s.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................

.........................................................................................................................


Conférence d’ouvertureSOUTIENS &SPONSORS 2017


4ème

RÉGION EUROPÉENNE DANS LE DOMAINE DE LA RECHERCHE

1er

SITE DE PRODUCTIONDE VACCINS EN EUROPE

800PME EN SANTÉ &

SCIENCES DE LA VIE

150 000EMPLOIS CRÉÉSEN SCIENCES DE

LA VIE

6GRANDS CENTRES

HOSPITALIERS

40INSTITUTS DE RECHERCHE

PUBLIC & PRIVÉ

3UNIVERSITÉS

D'ENSEIGNEMENT SUP. ET RECHERCHE

EN auvergne-Rhône-ALPES

D Y N a m i q u eUN ECOSYSTÉME

EN sc iencesDE LA V IE


Programme scientifique de l’ARC 1

L’ARC 1 concerne une thématique transversale de très large portée : la santé, un enjeu sociétal de première importance, mais aussi un domaine à fort potentiel de développement économique. Dans un souci de lisibilité scientifique, par rapport notamment aux divers réseaux et pôles déjà présents dans ce secteur à l’échelle de la Région Auvergne Rhône-Alpes, l’ARC a choisi de se placer résolument en amont des différents niveaux de la recherche.En particulier, l’ARC « Santé » a pour objectif de détecter et soutenir des projets de recherche émergents, originaux et d’excellente qualité, non encore financés par des programmes nationaux ou internationaux. Pour ces projets, la Région joue ainsi un rôle déterminant en matière d’impulsion, de structuration et de développement.L’ARC « Santé » est ancré sur l’ensemble des plates-formes technologiques dont se sont dotés les centres de recherche régionaux au cours des dernières années (biologie structurale, génomique fonctionnelle, bioinformatique, criblage de molécules chimiques...). De plus, il s’articule étroitement avec les projets d’autres ARC mis en place par la Région, en particulier l’ARC 2 « Qualité de Vie et Vieillissement » et l’ARC 3 « Environnement ».

Compétences et objectifs de l’ARC 1

> Structurer la recherche au niveau régional. Dans ce contexte, l’ARC 1 a défini 6 axes prioritaires : Infectiologie, Cancérologie, Nutrition pour la Santé, Molécules Bioactives, Bioinformatique, Sciences Humaines, Economiques et Sociales en Santé.> Promouvoir la recherche, en s’impliquant dans l’organisation et le financement d’animations scientifiques : colloques, manifestations, congrès, séminaires.> Former les futurs acteurs de la recherche, notamment par le biais d’attribution d’allocations permettant aux doctorants de préparer leur thèse pendant trois ans. > Favoriser les relations entre le monde académique et le monde industriel.> Instaurer un dialogue Science-Société afin de créer un lien avec la société civile à travers des évènements grand public.

Chiffres clés

99 unités de recherches / 193 équipes / 4 234 personnes (permanents et non-permanents).

RESPONSABLE : Pr. Alain J. COZZONECHARGÉE DE MISSION : Agnès DELEBASSEE-NABET

www.plass.com

Fondé en 1906, le Cabinet Plasseraud est l’un des leaders européens dans le domaine de la Propriété Intellectuelle.

Une équipe d’experts à votre service pour devenir le partenaire privilégié de

votre stratégie de développement.

www.plass.com

[email protected]

BREVETSMARQUES

NOMS DE DOMAINEDESSINS & MODÈLES

DROIT D’AUTEUR...

PARIS LYON DIJON LILLE TOULOUSE BORDEAUX PRAGUE SHANGAI

PUB V2.indd 1 25/09/2017 18:22:45


ASSURANCES ET MANAGEMENT DES RISQUES / SANTÉ, SOCIAL ET MÉDICO-SOCIAL

Partageons plus que l’assurance

Depuis 90 ans, Sham est le partenaire de référence des acteurs de la santé et de l’action sociale, proposant des solutions spécialisées

dans l’assurance et le management des risques d’activités.

Sham anticipe, s’adapte et propose des réponses concrètes au service de l’amélioration des pratiques et de la diminution du risque. De par son statut de société d’assurances mutuelle, Sham est bien plus

qu’un assureur, c’est un acteur engagé au quotidien au côté de ses clients.

www.sham.fr

Flash SHAM AP Instit 2017 260917 v3.indd 1 26/09/2017 16:08


.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

.....................................................................................................................

......................................................................................................................

NOTES


Conférence d’ouvertureBOÎTE À OUTILS


Lyonbiopôle est la structure d’interface entre les acteurs publics et privés de l’innovation en Auvergne-Rhône-Alpes. Le pôle favorise l’émergence de collaborations R&D pour permettre aux sociétés biotech et medtech de développer des produits et services répondant à des besoins de santé publique et d’accroître leur compétitivité internationale.

Lyonbiopôle stimule l’innovation en santé grâce aux actions menées autour de trois axes :

1 - FAVORISER L’ÉMERGENCE DE NOUVEAUX P A R T E N A R I AT S R & D

Le pôle propose chaque année un programme d’animation scientifique et clinique pour fédérer l’écosystème et les expertises de la région sur des axes stratégiques prioritaires en santé. Ce programme a pour objectif de dynamiser l’émergence de réseaux structurants thématiques et de projets collaboratifs ambitieux.

2 - A C C O M P A G N E R L A C O N S T R U C T I O N D E S PROJETS R&D COLLABORATIFS

Lyonbiopôle conseille les porteurs dans la structuration de leur consortium, l’organisation de leurs projets et les oriente vers les dispositifs de soutien à la R&D appropriés. Avec l’aide de son Groupe Technique, le pôle peut apporter son soutien aux projets pour renforcer leurs chances de succès à des appels à projets ciblés (labellisation, lettres de soutien).

3 - S U I V R E L E B O ND É R O U L E M E N T D E V O SP R O J E T S R & D

Par la suite, le pôle accompagne les projets en cours vers la mise sur le marché en donnant de la visibilité aux innovations développées. Les actions mises en place par le pôle visent à favoriser la valorisation des nouveaux produits et services par les acteurs de la filière.

ATELIERS

INNOVATION CLINIQUE

ANNUAIRES

EVENEMENTS INTERNATIONAUX

BLUESKY MEEETING

JOURNÉECOLLABORATIVE

FORMATION PI

COMITÉ DE SUIVI

COMMUNICATIONACCORD DE CONSORTIUM

3SUIVI DE PROJETS

1ANIMATION

SCIENTIFIQUE

INFOS SUR APPELS

FORMALISATION DU PROJET

VOLET EUROPE

GROUPE TECHNIQUE

SOUTIEN DES PROJETS

2USINE

A PROJETS

Nouveauxprojets

collaboratifs

> Nouveaux produits & services > Innovations technologiques, scientifiques et médicales > Développement économique

L A B E L L I S AT I O N

LYONBIOPÔLECatalyseur de l’innovation en santé


PRINCIPAUX DISPOSITIFS D’AIDE À L’INNOVATION

en santé pour les entreprises

IND

UST

RIAL

ISAT

ION

DÉV

ELO

PPEM

ENT

EXPÉ

RIM

ENTA

LRE

CHER

CHE

FO

ND

AMEN

TALE

RECH

ERCH

E

IND

UST

RIEL

LE

NIVEAU RÉGIONAL

AAP RECHERCHE

DE LA RÉGION

APPEL RDI BOOSTER

FRIFonds Régional

Innovation

PREUVE DE CONCEPT

CLARA

AAP HCL-

LYONBIÔPLE

SUBVENTION

SUBVENTIONpour des projets avec une assiette

> 500K€ SUBVENTION

Ouvert jusqu’au 31 oct. 2017

SUBVENTIONde 300 K€ par

projet

Ouverture : T4 2017

SUBVENTIONde 100 K€ par

projet

Ouvert

NIVEAU

ANRAppel

générique, LabCom,

Astrid

FUIFonds Unique

Interministériel

SUBVENTIONjusqu’à 800 K€

pour les projets public/privé

PRCE

Appel générique ouvert jusqu’au

26 oct. 2017

SUBVENTIONde 750 K€ à 2 M€

par projet


NATIONAL

PSPCProjets

Structurants Pour la

Compétitivité

RHURecherche Hospitalo-

Universitaire

CNI/CMIConcours

d'innovation (numérique/

mondial)

H2020 Projets

collaboratifs - DÉFI SANTÉ

INSTRUMENT PME

EUROSTAR IMIInnovative Médecine Initiative

NIVEAU EUROPÉEN

PIAVEProjets

Industrielsd'Avenir

SUBVENTION ET AVANCE

RÉCUPÉRABLEde 1 à 25 M€ par

projet

SUBVENTION ET AVANCE

RÉCUPÉRABLEde 3 à 25 M€ par

projet

Ouvert jusqu'au 15 janv. 2018

SUBVENTIONde 5 à 10 M€

par projet

SUBVENTION OU INVESTIS-

SEMENTselon la phase

concernée

SUBVENTIONtaux d'aide de

100%

Ouverture des appels le

27 oct. 2017


70%


30 à 40%

Ouverture jusqu'au

1er mars 2018


100 %

> Retrouvez le détail des appels sur notre site et notre application mobile :w w w . l y o n b i o p o l e . c o m / a p p e l s - a p r o j e t s


ANNUAIRES / ACTUALITÉS / AGENDA / APPELS A PROJETS / ESPACE ADHÉRENTS

Disponible dès maintenant sur

Apple Store Androïd Store

TÉLÉCHARGEZ NOTREAPPLICATION MOBILE....

Auvergne - Rhône - AlpesAuvergne - Rhône - Alpes


... ET PARTICIPEZ À NOTREAPPGAME

A l’occasion de la 11ème Journée Collaborative, Lyonbiopôle organise un AppGame !

Connectez-vous à votre espace adhérent et trouvez les indices cachés dans

l’application pour tenter de gagner :

un diner gastronomique pour 2 personnes, une enceinte bluetooth,

une action cam, ...

Photos non contractuelles // Réglement du jeu disponible sur demande


Pour cette 11ème édition de la Journée Collaborative, nous tenons à remercier :

La Région Auvergne-Rhône-Alpes pour nous avoir accueilli.

Le Cabinet Plasseraud et Sham, nos sponsors, ainsi que à l'ARC1 qui ont apporté leurs soutiens à cette édition.

Patrick Lévy pour la conférence d’ouverture -Innovations en santé et médecine du futur.

Les partenaires des tables rondes qui ont co-organisé avec Lyonbiopôle ces groupes et nous ont apporté leur soutien dans le montage et la réalisation de ces dernières. Nous remercions ainsi l’association ACCINOV, l’Institut de Recherche Technologique BIOASTER, le Centre Européen de Dermocosmétologie (CED), le Centre Européen de Nutrition pour la Santé (CENS), le cancéropôle CLARA, le cluster I-CARE, l’association MABDESIGN, l’agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), le pôle catalan BIOCAT, la mutuelle HARMONIE MUTUELLE et le Syndicat National de l’Industrie des TEchnologies Médicales (SNITEM).

Boehringer Ingelheim et les participants du Bluesky Meeting qui ont exposé leurs offres technologiques innovantes ou idées de projets ouverts aux collaborations, ainsi que les membres du comité de sélection pour leur expertise et leur implication dans l’évaluation des candidatures reçues.

Les animateurs des tables rondes qui ont partagé leurs connaissances, leur perception des enjeux prioritaires et qui ont mené les débats afin d’aboutir à la structuration d’idées fédératrices pour relever les défis de demain en terme d’innovation.

Nos administrateurs et financeurs pour leur soutien et la confiance qu’ils nous témoignent afin de favoriser le développement de Lyonbiopôle et des programmes structurants qui en ont émergé.

Les membres du Groupe Technique de Lyonbiopôle pour leur implication dans l’élaboration de la stratégie scientifique du pôle et le montage du programme de cette journée.

Tous les participants de la Journée Collaborative qui sont la raison du succès de cet évènement.

Et enfin, toute l’équipe de Lyonbiopôle pour sa mobilisation pendant mais aussi en dehors de l’évènement.

Nous espérons que cette journée vous aura permis d’initier de nouvelles collaborations et nous vous donnons rendez-vous en octobre 2018 pour une nouvelle édition.

L’équipe de Lyonbiopôle

REMERCIEMENTS


Avec le soutien de

Gold Sponsors

Avec la participation de

FOUNDERS AND BOARD MEMBERS

REPRESENTING PUBLIC RESEARCH REPRESENTING PRIVATE COMPANIES

BOARD MEMBERS

STATE AND LOCAL GOVERNMENTS SUPPORTS

w w w . l y o n b i o p o l e . c o m

LYONBIOPÔLEDomilyon - 321, avenue Jean Jaurès, F-69007 LyonT : +33 (0)4 72 76 63 30 - F : +33 (0)9 55 91 30 [email protected]

Auvergne Rhône Alpes- -

Documents

Lyonbiopôle€¦ · 11ÈME N N COLLABORATIVE DE LYON BIO PÔLE 10 OCTOBRE 017 . 3. Nous sommes très heureux de vous retrouver pour la 11. ème. édition de la Journée Collaborative